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Summary 
The Epstein-Barr virus (EBV) infects the majority of the population. The EBV M81 
strain isolated from a nasopharyngeal carcinoma (NPC) efficiently infects and 
transforms primary B cells, but it also induces potent virus lytic replication in a 
minority of these cells. We used recombinant viruses to reveal the function of the 
EBER RNAs. We found that the number of cells in which lytic replication takes place 
is increased both in vitro and in vivo by the non-coding RNA EBER2, but not by its 
homolog in the genome of the B95-8 strain. M81 and B95-8 EBER2 homologs 
displayed a limited number of polymorphisms, some of which influence their half-life 
and expression levels. M81 EBER2 modified the expression of a large number of 
cellular genes including CXCL8. This chemokine was able to compensate the absence 
of EBER2, suggesting that it represents the main target of this non-coding RNA. We 
found that the exosomal fraction of B cells infected with wild type M81 carries the 
EBER molecules, are able to increase CXCL8 and BZLF1 production. The effect of 
EBER2 on EBV lytic replication required a functional TLR7, a sensor of viral single-
stranded RNA (ssRNA). Therefore, we propose a model in which EBERs are vehicled 
into the exosomal fraction of infected B cells to initiate lytic replication in a paracrine 
manner through CXCL8 secretion induced by TLR7 stimulation. These results 
indicate that EBERs NPC-derived virus variant contribute to lytic replication in B 
cells and activate production of a chemokine involved in carcinogenesis. 
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Zusammenfassung 
Ein Großteil der Bevölkerung ist mit dem Epstein-Barr-Virus (EBV) infiziert. Der aus 
Nasopharyngealkarzinomen isolierte Virusstamm M81 infiziert und transformiert 
primäre B-Zellen, kann aber auch in einem kleinen Teil dieser Zellen eine lytische 
Replikation induzieren. Wir nutzten rekombinante Viren um die Funktion der EBER 
RNAs zu untersuchen. Wir konnten zeigen, dass die Anzahl der Zellen, in welchen 
lytische Replikation stattfand, durch die nicht-kodierende RNA EBER2 sowohl in 
vitro als auch in vivo erhöht wird. Dies war allerdings nicht bei dem Homolog aus 
dem 95-8 Genom der Fall. Die M81 und B95-8 EBER2 Homologe haben eine 
bestimmte Zahl ein Polymorphismen, teilweise können diese ihre Halbwertszeit und 
Expressionslevel beeinflussen. M81 EBER2 hatte Auswirkungen auf die Expression 
vieler zellulärer Gene, darunter auch CXCL8. Dieses Chemokin konnte ein Fehlen 
von EBER2 kompensieren, was ein Zeichen dafür sein könnte, dass CXCL8 das 
Hauptziel von EBER2 ist. Wir fanden heraus, dass Exosomen von M81-infizierten B-
Zellen EBER-Moleküle enthalten, welche die CXCL8 und BZLF1-Produktion 
erhöhen können. Die Wirkung von EBER2 auf die lytische Replikation von EBV 
benötigte einen funktionalen TLR7, welcher ein Sensor für virale einzelsträngige 
RNA (ssRNA) ist. Deswegen schlagen wir ein Modell vor, in welchem EBER in 
Exosomen von infizierten B-Zellen gebracht werden, um so eine lytische Replikation 
durch TLR7-induzierte CXCL8 Sekretion zu induzieren. Diese Resultate weisen 
darauf hin, dass EBER aus NPC-abgeleiteten Virusstämmen zur lytischen Replikation 
in B-Zellen beitragen und die Produktion eines Chemokins aktivieren, welches in der 
Karzinogenese involviert ist. 
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1 Introduction 
1.1 EBV and its related diseases 
Epstein-Barr Virus (EBV) is the first discovered human tumor virus. In March 1964, 
Anthony Epstein and other colleagues identified herpesvirus-like particles in cultured 
tumor cells derived from African Burkitt’s lymphoma tissue (Epstein et al., 1964). At 
that time, the idea that a virus could cause human tumor was met with some 
skepticism because the theory that cancer was infectious had been dismissed in the 
previous century. The Epstein-Barr Virus (EBV) (Figure 1.1 A), also called human 
herpesvirus 4 (HHV-4) is a common human virus that can cause both infectious 
mononucleosis and lymphoproliferative disease. EBV infects more than 90% of the 
adult population between 35-40 years old in the U.S, usually without clinical 
consequences, particularly when people are infected during childhood (Liebowitz D, 
1993).   
Because EBV belongs to the member of the herpesvirus family, it is very 
efficient at establishing a long-term latent infection in B cells. Previous exposure to 
EBV can be detected by serology, and latent forms of EBV can be readily detected by 
molecular methods in a small percentage of B-lymphocytes from healthy individuals.  
EBV is associated with the development of cancers such as Burkitt’s lymphoma, 
Hodgkin’s lymphoma, and nasopharyngeal carcinoma. The virus is able to infect host 
B-cells and epithelia, and induce proliferation of its host via a non-lytic mechanism. 
During this latent process, virus-encoded nuclear proteins (EBNAs) and latent 
membrane proteins (LMPs) are expressed in infected host cells (Young and 
Rickinson, 2004). 
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EBV genome: The Epstein-Barr virus is a Baltimore Class I virus of the family 
Herpesviridae. Researchers used electron microscopy to describe these viral particles 
and found that EBV was very similar in structure to Herpes simplex virions (Fig. 1.1 
A) (Epstein et al., 1964). The EBV genome is made of double-stranded DNA and is 
around 180 kb long (Baer et al., 1984). Herpes viruses possess relatively big 
genomes; Herpes simplex has a 152-kilobase genome (Mahiet et al., 2012). The open 
reading frames (ORFs) of EBV are generally broken up into separate lytic and latent 
sections. While most of the viral genes encode proteins, some of the latent genes 
remain noncoding (EBERs and microRNAs). During latent infection, the EBV 
genome exists in a circularized form localized in the host cell nucleus (Young and 
Rickinson, 2004). The open reading frames for the LMPs and EBNAs are clustered 
separately within the episomes (Fig. 1.1 B). 
 (A)                                                                              (C) 
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                    (B) 
                               
Fig. 1.1 (A) Original micrographs (EM) of cultured Burkitt’s Lymphoma tissue 
published by Epstein and Barr in 1964. V indicates the presence of EBV virions. (B) 
A general diagram of an Epstein-Barr Virus dsDNA episome. Note the clustering of 
open reading frames for EBNA and LMP genes and the location of the origin of 
replication, oriP. The green arrows show the direction of transcription initiation 
during latency III (Young and Rickinson, 2004). (C) A general diagram of the 
structure of a herpesvirus virion (Wikipedia). The dsDNA genome is wrapped around 
a central nucleo-protein. Spike glycoproteins (not labeled) on the surface play a role 
in host cell entry. 
EBV virion structure: Epstein and Barr observed that this lymphoma-associated 
virus was around 20% smaller in size than those typical Herpes simplex virions 
(Epstein et al., 1964). Similar to other Herpesviruses, the innermost part of the EBV 
virion consists of a copy of linearized viral DNA wrapped around a central nucleo-
protein core (Fig. 1.1 C). The core of the virion is surrounded by a nucleocapsid, a 
layer of protein tegument, and an outer envelope with spike glycoproteins (Liebowitz 
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D, 1993). This nucleocapsid consists of a polymer of viral capsid proteins that play a 
key role in wrapping the viral genome into the core of the nucleocapsid layer and the 
delivery of the viral DNA at the nuclear membrane (Kieff et al., 1982). The tegument 
proteins display multiple enzymatic activities that are not only important for the 
infection but also for the maturation of the virus (Kalejta, 2008). Many of these 
glycoproteins are important for host-cell entry and fusion mechanisms. Infected host 
cells release EBV virus particles exclusively during the lytic cycle. 
EBV-related diseases: EBV is transmitted orally and is often acquired during 
childhood. Primary EBV infection is usually clinically silent or not different from the 
usual minor respiratory infections that occur in children. In developed countries, 
infection with EBV is often delayed until adolescence. Infection with EBV may also 
develop unnoticed in this case, although some people develop infectious 
mononucleosis, which is described by symptoms of sore throat, lymphadenopathy, 
fever and fatigue (Balfour et al., 2013). In both cases, EBV infection is countered by a 
robust immune response, natural killer cells, CD8+ cytotoxic T-cells and CD4+ 
helper T-cells (Rickinson et al., 2014). This response can be very potent and the 
consequences of infectious mononucleosis are thought to come from an exuberant 
immune response to infection. Nevertheless, the immune system cannot clear the 
virus that establishes permanent infection in the host’s B-lymphocytes, evading anti-
viral immunity response by silencing viral protein expression. This strategy enables 
EBV to persist for the lifetime of the host as a latent infection. In order to be 
transmitted to new hosts, some of the B cells carrying EBV undergo reactivation, 
producing new progeny virus in the oropharynx for transmission to susceptible 
individuals (Taylor et al., 2015). 
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The co-existence between EBV and its host means that most people have no long-
term health effects from this infection. Although relatively benign in most people, 
EBV has powerful growth transforming potential and is classified as a group I 
carcinogen by the World Health Organization. EBV is associated with several distinct 
lymphomas: Burkitt lymphoma, Hodgkin lymphoma, T/NK lymphoma and about 
10% of diffuse large B cell lymphomas. EBV is also a problem in the transplant 
setting, where iatrogenic immunosuppression may result in post transplant 
lymphoproliferative disease (PTLD) (Rickinson et al., 2014). EBV has the ability to 
infect and transform epithelial cells in vivo. EBV is associated with 10% of gastric 
carcinomas and with almost all cases of the non-keratinizing subtype of 
nasopharyngeal carcinoma (NPC). This subtype represents most cases (>95%) of 
NPC in Southeast Asia where the disease is endemic. Taken together, EBV is related 
to an estimated 200,000 cases of cancer each year, representing 1% of all cancers 
worldwide (Parkin, 2006). 
All EBV-associated malignancies express viral proteins but the viral protein 
expression pattern is different in different diseases (Table 1.1). Post-transplant 
lymphomas, particularly those that arise in the first year after transplantation when 
immunosuppression is greatest, express all nine EBV latent proteins. These comprise 
six Epstein-Barr Nuclear Antigens (EBNAs) and three Latent Membrane Proteins 
(LMPs). The EBNA 3A, 3B, and 3C proteins, which are good CD8+ T-cell targets, 
are expressed (Taylor et al., 2015). In contrast, a lower number of EBV proteins is 
expressed in the remaining EBV-associated malignancies, possibly reflecting their 
origin in people who are not overtly immunosuppressed. 
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Table. 1.1 EBV-associated malignancies and the viral proteins in the tumor cells 
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1.2 The EBV infection modes 
 
1.2.1 Lytic life cycle 
Like all herpesviruses, EBV exhibits two life cycles: latency and lytic replication 
phase that leads to the generation of progeny viruses (Kieff and Rickinson, 2007). 
Although the EBV lytic life cycle is more rarely observed than the latent cycle, it is 
very important since it is the only way that the virus may produce virions and be 
transmitted horizontally between hosts or cells. Increased free virion levels are 
observed in immunosuppressive diseases like AIDS in the blood. While virions are 
often found in the saliva of infected hosts, little or no lytic-infected cells are typically 
detected in the body (Swaminathan S., 2009). Human cytotoxic T-cells are 
particularly good at recognizing and killing lytically infected cells expressing early 
stage lytic genes. Although lytic replication contributes to drive EBV spread in human 
populations, latent infection is more common in infected cells. Alpha and Beta 
herpesviruses have evolved elaborate mechanisms for lytic gene concealment from 
the host immune system; however, EBV has few mechanisms to evade immune-
mediated destruction of lytic-infected cells. For example, Herpes simplex virus is able 
to inhibit host Major Histocombatibility Complex (MHC) expression, which reduces 
B-cell antigen presentation and recognized by cytotoxic T-cells. In contrast to other 
herpes viruses, EBV have a different mechanism to evade the host immune response. 
EBV mainly relies on a latent replication cycle in which it copies its genome within 
dividing host B-cells using the replication machinery of the host (Steven et al., 1997). 
Therefore, unlike other herpesviruses that rely on lytic replication for spread within a 
host, EBV relies more on its latent replication. Because latent mechanisms are 
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responsible for persistence in the host, EBV is not under significant selective pressure 
to develop elaborate lytic immune avoidance traits. 
Latent infection plays a primary role in the development of lymphoproliferative 
disease (LPD) in EBV infected individuals. The role of lytic replication in EBV-
associated malignancies is not well understood. Researches reported that EBV 
mutants (B95-8 strain) that cannot undergo lytic viral replication are defective in 
promoting EBV-mediated lymphoproliferative disease (LPD). In more detail, they 
found that early-passage lymphoblastoid cell lines (LCLs) derived from EBV mutants 
with a deletion of either viral immediate-early gene (BZLF1) grew similarly to wild-
type (WT) virus LCLs in vitro but were deficient in producing LPD when inoculated 
into SCID mice. In addition, lytic infection contributes to stimulate the secretion of 
paracrine factors that may promote the growth of latently infected B-cell lines. While 
it may have a more diffuse effect than the latent mechanism, EBV lytic infection- 
mediated signaling may contributes to the development of lymphoproliferative 
disease (Hong et al., 2005). 
The lytic cycle produces progeny viruses that can target host cells, such as B cells. To 
enter B cells, viral glycoprotein gp350 bind to cellular receptor CD21 (also known as 
CR2) (Nemerow et al., 1987). Then, viral glycoprotein gp42 interacts with 
cellular MHC class II molecules. Subsequently, fusion between the viral envelope and 
endocytotic membrane is mediated by gH/gL and gB (Kirschner et al., 2006). 
Following fusion, the viral capsid enters into the cytoplasm and is transported to the 
nuclear membrane by microtubule-mediated transport. The EBV viral genome is 
released into the nucleus through a nuclear pore. During the lytic replication cycle, the 
viral genome replicates in the nucleus (Daikoku et al., 2005). The viral genome is 
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replicated using an EBV DNA polymerase, which stimulates the production of viral 
structural proteins. Viral particles are assembled in the nucleus (Henson et al., 2009). 
After full particles are assembled, they bud out of the nuclear membrane, then through 
the Golgi membrane.  
Two immediate-early lytic genes including BZLF1 (also known as Zta, associated 
with its product gene ZEBRA) and BRLF1 (associated with its product gene Rta) 
cooperate to promote most of the lytic genes transcription. Early lytic gene products 
perform functions such as replication, metabolism, and blockade of antigen 
processing. Finally, late lytic gene products tend to be proteins with structural roles, 
such as VCA, which forms the viral capsid. Other late lytic gene products, such as 
BCRF1, help EBV evade the immune system. 
1.2.2 Latent infection 
In most cases, once EBV virions accomplish primary infection of B-lymphocytes, the 
virus mainly replicates by a latent form (Jochum et al., 2012). This results in the 
transformation of B-cells into proliferating lymphoblastoid cell lines (LCLs) (Young 
and Rickinson, 2004). The latent replication cycle is defined in two aspects: 1) No 
production of virions, and 2) the production of few viral proteins and transcripts. 
These latent viral proteins activate the proliferation of host B-cells and contribute to 
lymphoproliferative disease (Cesarman, 2011).  
EBV can exhibit three latency programs: Latency I, Latency II, and Latency III. In 
latency I, only EBNA1 is expressed (Cesarman, 2011), while in latency II EBNA1 is 
expressed along with the LMP proteins (Young and Rickinson, 2004). In Latency III, 
the six EBNAs and the three LMP proteins (LMP1, 2A, and 2B) are produced. The 
transcription of EBV genome initiates at either the Wp or Cp promoter. Differential 
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splicing of the same long transcript generates the different EBNA mRNA. In vitro, 
LCLs typically display latency III-like expression profiles (Cesarman, 2011). B-cells 
must have latency III expression profiles for successful generation of LCLs in 
vitro (Klein and Ernberg, 2007). In addition to these latent proteins, several non-
coding RNAs (EBERs) and micro-RNAs are also expressed during all these latency 
types (Fok et al., 2006; Young and Rickinson, 2004). 
1.2.3 Reactivation from latent phase to lytic phase 
Latent EBV in B cells can be reactivated to switch to lytic replication. This is known 
to happen in vivo, but the precise mechanism why EBV is reactivated is unknown. In 
vitro, EBV latency in B cells can be reactivated by stimulating the B cell receptor, so 
reactivation in vivo probably happens when latently infected B cells respond to 
unrelated infections (Odumade et al., 2011). In vitro, EBV latency in B cells can also 
be reactivated by treating with sodium butyrate or TPA. In most EBV-positive cell 
lines, BZLF1 protein alone is sufficient to induce the switch from latency to lytic 
replication.   
BZLF1 interacts directly with histone acetylating complexes, such as CBP and p300 
and the general transcription factors TFIID and TFIIA. During viral reactivation 
(EBV genome is highly methylated in cells), BZLF1 initially activates the 
transcription of BRLF1 gene. BZLF1 and BRLF1 then promote the transcription of 
many of the early lytic viral genes that often contain binding sites for both (Wille et 
al., 2013). They are both needed for expression of many, but not all, of the early-lytic 
genes in the EBV genome (Feederle et al., 2000). BZLF1 also makes contributions to 
the lytic EBV DNA replication, binding directly to many of the essential ZRE sites 
located within the lytic origin of replication, oriLyt. The direct interactions between 
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BZLF1 and core EBV replication proteins likely promote the formation of replication 
complexes.  
BRLF1 can also induce the switch from latency to lytic phase in some EBV-positive 
cell lines, especially in epithelial cells. BRLF1 directly binds to GC-rich motifs 
known as R-responsive elements (RREs) (consensus 5’-GNCCN9GGNG-3’) located 
within the promoters of early lytic genes (Heilmann et al., 2012). R directly interacts 
with both the general cellular transcription factors, such as TBP and TFIIB and the 
histone acetylating complex CBP and p300. Previous published data from transient 
transfection reporter assays suggest that BRLF1 activates both its own promoter and 
the BZLF1 promoter by indirect mechanisms in which the Sp1, MCAF1 and Oct-1 
transcription factors, and some cellular kinases are involved in this process (Adamson 
et al., 2000; Darr et al., 2001; Ragoczy and Miller, 2001; Robinson et al., 2011). 
However, given that the strong enhancer activity of BRLF1-bound RREs, it is 
speculated that BRLF1 directly activates the BZLF1/BRLF1 transcription in the 
context of the EBV genome (Heilmann et al., 2012). At least two EBV-encoded 
proteins are involved in the ability of BRLF1 to regulate viral latency. The early-lytic 
viral protein BRRF1 activates phosphorylation of c-Jun and cooperates with BRLF1 
to induce BZLF1 promoter transcription in the context of the intact EBV genome 
(Hagemeier et al., 2011; Hong et al., 2004). In contrast, the early-lytic EBV protein 
LF2 directly inhibits the activity of BRLF1, therefore, it limits viral lytic replication 
(Calderwood et al., 2008). The opposite roles of BRRF1 and LF2 might help to fine-
tune the transcriptional effects of BRLF1 during the various stages of EBV lytic 
replication. 
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1.3 EBV-encoded small RNAs (EBERs) 
1.3.1 Generalities 
Epstein-Barr virus (EBV) expresses two noncoding RNAs called EBER1 (EBV-
encoded RNA 1) and EBER2, that are 167 and 173 nucleotides (nts) long, 
respectively. They are transcribed by RNA polymerase III (Howe and Shu 1989). The 
EBERs are expressed in all forms of EBV latency and also during lytic replication. 
They are the most abundant viral transcripts in latently EBV-infected cells. EBER1 
accumulates to 106 and EBER2 to 2.5 x 105 copies per infected cell. Currently, 
EBERs are used as preferential target molecules in in situ hybridization (ISH) 
detection of EBV-infected cells in tissues (Chang et al., 1992) and are considered a 
good marker to detect the presence of EBV, as they are highly expressed in EBV-
infected cells. Previous papers have shown that EBERs are oncogenic. Expression of 
these RNAs in B-lymphocytes can induce colony formation in soft agar and tumor 
formation in nude mice (Komano et al., 1999; Ruf et al., 2000). Furthermore, EBERs 
can induce resistance to interferon-alpha-induced apoptosis in BL cells (Nanbo and 
Takada, 2002). Previous studies have also demonstrated that EBERs can induce the 
transcription of various cytokines, such as interleukin-10 (IL-10) in BL cells, insulin-
like growth factor-1 (IGF1) in epithelial cells and IL-9 in T cells. These cytokines can 
subsequently act as autocrine growth factors for EBV-infected cancer cells (Iwakiri et 
al., 2003; Iwakiri et al., 2005; Kitagawa et al., 2000; Yang et al., 2004). More recent 
studies have shown that EBER1 is sufficient to elicit these phenotypes, suggesting 
that EBER2 is redundant (Houmani et al., 2009). The EBERs were reported to 
promote the pathogenic consequence of EBV infection by modulating innate immune 
signals (Iwakiri et al., 2009; Samanta et al., 2006; Samanta et al., 2008). 
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1.3.2 Structure of EBERs 
EBER1 and EBER2 are short, nuclear-enriched non-coding RNAs that are 166 and 
172 nucleotides (nts) in length, respectively (Rosa et al., 1981). These two RNAs 
display 54% sequence homology. The EBER genes are separated by 161 base pairs 
and are transcribed from left to right on the EBV map. Although these two EBERs 
show only limited sequence identity (54%), they exhibit striking similarities in their 
secondary structures and form several short stem loops (Fig. 1.2, (Rosa et al., 1981). 
However, the secondary structures are not identical, suggesting that EBER1 and 
EBER2 might have distinct functions.  
EBER1 is highly conserved in its primary sequence among multiple EBV strains with 
only 5 polymorphisms as shown in Table 1.2, suggesting that the EBERs are very 
important in the virus life cycle. EBER1’s secondary structure is very stable, and is 
organized into five conserved hairpins (Fig. 1.2) radiating from two multi-branch loop 
structures. In addition to its hairpins, EBER1 possesses a 9 nt single-stranded tail at 
its 3′ end. This RNA structure provides a platform for binding of host proteins to form 
EBER1 ribonucleoprotein (RNP). EBER2 also displays some polymorphisms among 
multiple EBV strains (Table 1.3). The distribution of the different EBER2 
polymorphisms in lymphoma and in EBV-associated gastric carcinoma (EBVaGC) is 
nearly identical, however, there are some polymorphisms that are seen more 
frequently in nasopharyngeal carcinoma (NPC) as shown in Table 1.3 and Fig. 1.2, 
suggesting that NPCs carry a specific type of EBER2 that might have unique 
functions.  
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Table. 1.2 EBER1 polymorphisms among 137 EBV strains  
 
In all other 130 EBV strains, EBER1 is identical to B95.8; HN4 is identical to VGO.  
Communication from R. Poirey (DKFZ) 
 
Table. 1.3 EBER2 polymorphisms among multiple EBV strains  
 
B95-8 (derived from IM) is equal to BL36, sLCL-1.02, 11, sLCL-IS1.04, 18, X50-7. 
(7% of total EBV genomes) 
Akata (derived from Burkitt’s lymphoma) is equal to EBVaGC1to9, GC1 (SNU719), 
and to the majority of other EBV strains (about 70% of total EBV genomes). 
M81 is identical to HKNPC1to9 (about 20% of total EBV genomes).  
BL, Burkitt lymphomas; EBVaGC, EBV associated gastric carcinomas; NPC, 
Nasopharyngeal carcinoma; LCL, Lymphoblastoid cell lines; 
Communication from R. Poirey (DKFZ) 
 
 
 
Strains	 20	 52	 106	 116	 160	
B95-8	 A	 T	 T	 C	 C	
Wewak	1	 T	 T	 T	 C	 C	
sLCL-TM1.16	 A	 C	 T	 C	 C	
HN4	 A	 T	 G	 C	 C	
SLCL1.19	 A	 T	 T	 T	 C	
HL05	 A	 T	 T	 C	 G	
Groups 44 46 57 61 93 168 Ratio 
B95-8 T A A A A A 7.0% 
Akata T A A A A G 68.6% 
M81 G T G T C G 16.3% 
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Fig. 1.2 Secondary structures of the EBER1, showing potential protein binding sites 
for L22, PKR, and La in red and blue. EBER1 structure is reproduced from Rosa et 
al. EBER2 structure is reproduced from Lee et al. The blue region (+41 to +64) can 
bind to the terminal repeat (TR) of the EBV genome. The red positions display 
polymorphism between B95-8 and M81 strains. In M81, at position 44 is G, position 
46 is U, position 57 is G, position 61 is U, position 93 is C and position 168 is G. 
RNase H-sensitive regions are indicated in orange. The region hybridizing to the 
antisense oligonucleotides (ASOs) used in capture hybridization analysis of RNA 
targets (CHART) is in red. EBER, Epstein-Barr virus-encoded RNA. 
1.3.3 Synthesis and expression of EBERs 
EBERs are transcribed by RNA polymerase III. These genes show the typical 
intragenic Box A and Box B RNA Pol III promoter sequences. Furthermore, they 
contain three typical upstream promoter elements including a TATA box as well as 
ATF- and Sp1-like promoter elements as shown in Fig. 1.3. Sp1-like promoter 
element binds Sp1 protein or a related protein and ATF-like promoter element binds 
the activating transcription factor (ATF).  These three upstream elements are typical 
of Pol II promoters and they together stimulate in vivo EBERs expression 50-fold. 
Both Pol II and Pol III promoter elements stimulate Pol III, but not Pol II-modulated 
transcription in EBV-transformed lymphocytes (Howe and Shu, 1989). A sequence 
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alignment between M81 and B95-8 shows that M81 and B95-8 carry the same Pol II 
promoter elements for EBER2 as shown in Fig. 1.4, however, they display one 
difference at position 57 in the polymerase III control regions as shown in Fig. 1.5.  
The level of EBER expression appears to be correlated to the EBV DNA molecule 
copy number in infected cells (Arrand and Rymo, 1982). Upon EBV infection of 
primary B-lymphocytes, EBNA2 is expressed firstly at 6 h post infection, followed by 
other EBNA genes, latent membrane protein genes (LMPs) and by the EBERs. The 
non-transforming P3HR-1 strain that carries a deletion of the EBNA2 locus expresses 
only the EBNA-leader protein (EBNA-LP) and trace amounts of EBER1 in primary B 
lymphocytes, however, the same virus can express EBNA1, EBNA3(s), EBNA-LP 
and EBERs upon infection of EBV-negative BL cell lines (Rooney et al., 1989). 
These findings indicate that EBERs expression depends on the host cell, perhaps 
through products specific for the cell cycle or the state of B-cell differentiation 
induced by EBNA2.  
EBER expression seems to be also influenced by the stage of viral life cycle. An early 
paper demonstrated that EBER transcription was down regulated during the switch 
from latent infection to lytic EBV replication. In contrast, the expression of EBERs 
remains unaltered within 72 h after the induction of lytic replication (Greifenegger et 
al., 1998). Although EBER1 and EBER2 are transcribed at approximately equal rates, 
EBER1 is present at about 10-fold higher levels compared to EBER2, probably due to 
the longer half-life of EBER1. Indeed, in the presence of actinomycin D, the half-
lives of EBER1 and EBER2 are 8 to 9 h and 45 min, respectively (Clarke et al., 
1992).  
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Fig. 1.3 Promoter structure of the Epstein–Barr virus-encoded small RNA (EBER)-2-
gene, showing the upstream region containing TATA box (−23 to −28) and 
transcription factor ATF (−40 to −55), and Sp1 (−56 to −77) binding sites and the 
intragenic polymerase III control regions, box A (+11 to +20) and box B (+51 to 
+60). “+1” is the transcription start site (TSS) of the EBER2 transcript. Positive 
values are downstream location after the TSS of the EBER2 transcript. Negative 
values are upstream position before the TSS of the EBER2 transcript.  
 
 
    
Fig. 1.4 A sequence alignment in Pol II promoter elements for EBER2 between M81 
and B95-8.  
 
Fig. 1.5 A sequence alignment in Box A and Box B for EBER2 between M81 and 
B95-8.  
Sp1	 ATF	
-56 to -77 
-40 to -55 
TATA	
-23 to -28 
+1 Box	A	 Box	B	
+11 to +20 +51 to +60 
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1.3.4 Localization of EBERs 
EBERs are found mainly in the nucleus and generate an intense nuclear signal after 
EBER ISH staining (Howe and Steitz, 1986). Fig. 1.6 shows an example of an EBER 
ISH staining. However, high-resolution ISH using confocal laser scanning 
microscopy has shown that EBERs are found in both the cytoplasm and nuclei of 
interphase cells (Schwemmle et al., 1992). Researchers previously reported that 
EBERs are found in a complex with the lupus antigen (La) protein (Iwakiri et al., 
2009). As the EBERs can bind to types of proteins that are not only restricted to the 
nucleus but are also located in the cytoplasm, it was speculated that this is a reason 
why EBERs could also localize in the cytoplasm (Lee et al., 2012; Samanta et al., 
2006).  
 
Fig. 1.6 This picture shows an example in situ hybridization with an EBER specific 
probe. We can see that EBERs can generate an intense nuclear signal after EBER ISH 
staining (Lin et al., 2015).  
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1.3.5 Proteins interacting with EBERs 
La protein:  
EBERs exist in the form of nuclear ribonucleoprotein (RNP) complexes that can be 
immunoprecipitated with anti-La antibodies (Lerner et al., 1981). The La protein 
binds the short oligouridylate stretch at the 3' ends of polymerase III transcripts, 
thereby facilitating the correct folding and maturation of RNA polymerase III 
transcripts (Gottlieb and Steitz, 1989). This binding is transient for most RNAs but 
stable for the EBERs (Howe and Shu, 1988).  Abundantly expressed EBERs make 
stable complexes with La protein, and, therefore, the amount of free La protein is 
significantly reduced in EBV-infected cells (Glickman et al., 1988). Since the La 
protein plays an important role in the biogenesis of RNA polymerase III transcripts, 
the formation of stable complexes between La and EBERs is expected to affect the 
interaction between La and RNA polymerase III in EBV-infected cells.  
La is mainly located in the nucleus, however, it can also be found in the cytoplasm 
under certain conditions (Bachmann et al., 1989; Meerovitch et al., 1993). The 
poliovirus-mediated cleavage of the La nuclear localization signals was reported to 
result in the shuttling of La from the nucleus to the cytoplasm.  Their results suggest 
that La protein is involved in poliovirus internal initiation of translation and might 
function through a similar mechanism in the translation of cellular mRNAs 
(Meerovitch et al., 1993). A recent study indicated that the EBER-La interaction 
complex is making contributions to the secretion of EBER from EBV-infected cells 
into the extracellular medium, because EBER is primarily released when it forms a 
complex with the La protein (Iwakiri et al., 2009). The consequence of EBER-La 
interaction remains unknown, however, it seems likely that it plays some roles in 
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general replication, transcription, or RNA processing in EBV-infected cells. 
PKR: 
The adenovirus-encoded RNAs, VA1 and VA2, are small ncRNAs that are 
transcribed by RNA pol III and that are essential for adenovirus replication and that 
have been shown to inhibit PKR-mediated shutdown of translation (Shiroki et al., 
1999). Although EBERs and VAs display no high sequence homology, they exhibit 
similarities in size, degree of secondary structure and genomic organization as shown 
in Fig. 1.7 (Akusjarvi et al., 1980). Intriguingly, the EBERs can functionally 
substitute for VAI/II and partly rescue replication of adenoviruses lacking VAI/II 
(Bhat and Thimmappaya, 1983). Similar to VA RNAs, EBERs can bind to the 
double-stranded RNA-dependent protein kinase (PKR), a serine/threonine kinase that 
can be induced by IFNα.  PKR plays a role in mediating the antiviral effects of IFNα 
(Fok et al., 2006; Sharp et al., 1993). Previous study demonstrated that PKR could 
bind to the stem-loop IV of EBER1 as shown in Fig. 1.2 (Vuyisich et al., 2002). PKR 
phosphorylates the α-subunit of the protein synthesis initiation factor eIF2 and thus 
results in translational inhibition at the level of initiation. In vitro assays have 
demonstrated that EBERs can inhibit PKR activation and block the phosphorylation 
of eIF2α, thus blocking the eIF2α-mediated inhibition of protein synthesis (Katze et 
al., 1991; Sharp et al., 1993). In BL cells, EBERs were reported to confer resistance to 
IFN α induced apoptosis by directly binding to PKR and inhibiting its 
phosphorylation (Nanbo et al., 2002). A study also reported that EBERs/VAs 
preferentially bind to the latent dephosphorylated form of PKR, with a similar affinity 
to that of dsRNA activators. However, EBERs/VAs prevent PKR dimerization, which 
is required for efficient PKR trans-autophosphorylation. Consequently, the 
phosphorylation of the PKR substrate is blocked, and protein synthesis continues 
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unhindered (McKenna et al., 2007).  
 
Fig. 1.7 The Secondary structure of VA RNAs. The structure of VA RNA1 (A) and 
two possible structures for VA RNAII (B and C) were derived by computer analysis. 
Reproduced from Akusjärvi et al (Akusjarvi et al., 1980). 
L22: 
EBERs exist in the form of nuclear ribonucleoprotein (RNP) complexes that can be 
immunoprecipitated with anti-La antibodies (Lerner et al., 1981). A second highly 
abundant EBER-associated protein (EAP) was also identified in La-containing RNP 
complexes (Toczyski and Steitz, 1991). EBER1 was reported to mainly bind to EAP 
and EAP was subsequently confirmed to be the ribosomal protein L22 (Toczyski et 
al., 1994; Toczyski and Steitz, 1993). Although its functions are not well known, L22 
was identified as the target of chromosomal translocation in certain leukemia-
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associated proteins (Nucifora et al., 1993), indicating that L22 expression levels might 
play an essential role in cell transformation. A study also suggested that the cellular 
functions of L22 might involve its association with the human telomerase (Le et al., 
2000), and L22 has also been shown to interact with many other small viral RNAs 
(Leopardi et al., 1997; Wood et al., 2001).  
L22 is located in the nucleolus and cytoplasm of primary uninfected human B-
lymphocytes. However, in EBV-infected cells, probably 30%–50% of the L22 
interacts with EBER1 and L22 relocalizes to the nucleoplasm (Toczyski et al., 1994). 
This suggests that the L22-EBER1 interaction can cause an abnormal cellular 
redistribution of L22 in EBV-infected cells. A recent study showed that the 
distribution of L22 was predominately located in the cytoplasm in EBV-transformed 
lymphoblastoid cell lines (LCLs), but that this process is independent of EBER1 
(Gregorovic et al., 2011). Previous studies have reported that EBER1 contains 
multiple L22-binding sites, including stem-loop III (Toczyski and Steitz, 1993), stem-
loop IV (Dobbelstein and Shenk, 1995), and stem-loop I (Fok et al., 2006). The 
existence of these multiple L22 binding domains suggest that most EBERs probably 
form complexes with L22 in vivo and that EBERs might modulate protein translation 
(Fok et al., 2006). A previous study reported that L22 and PKR compete for a 
common binding site on EBER1. L22 hampers the ability of EBERs to inhibit PKR 
activation by dsRNA through this competition. Transient introduction of EBER1 in 
murine embryonic fibroblasts causes reporter gene β-galactosidase activity 
upregulation and partially blocks the inhibitory effects of PKR. However, EBER1 is 
also stimulatory when transfected into PKR-null cells, suggesting a function that is 
PKR-independent. L22 expression prevents both the PKR-dependent and -
independent effects of EBER1 in vivo. These findings suggest that the L22-EBER1 
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interaction can reduce the biological effect of viral ncRNA, including PKR inhibition 
and any other mechanism by which EBER1 induces gene expression (Elia et al., 
2004).  
Other interacting proteins: 
Recent studies have reported that yet other cellular proteins can interact with EBERs. 
Pathogens infection can evoke the host innate immune responses that result in the 
elimination of invading pathogens. Cells express a limited number of germ-line 
encoded receptors known as pattern-recognition receptors (PRR) that specifically 
recognize pathogen-associated molecular patterns within microbes. The retinoic acid-
inducible gene I (RIG-I) like receptor (RLR) family, which includes RIG-I 
(Yoneyama et al., 2004), melanoma differentiation-associated gene (Mda)-5 (Kang et 
al., 2002), and LGP2 (Yoneyama and Fujita, 2007), comprises cytoplasmic proteins 
that recognize viral RNA. RLRs are known to play a key role in IFN-inducible 
antiviral effects (Meylan and Tschopp, 2006). When RIG-I is activated by an 
interaction with viral dsRNA, it can initiate signaling pathways that result in the 
induction of protective cellular genes, including type I IFNs and inflammatory 
cytokines. RIG-I contains a C-terminal DExD/H-box RNA helicase domain and an N-
terminal caspase recruitment domain (CARD). The helicase domain is responsible for 
dsRNA recognition, and the CARD domain activates downstream signaling cascades 
via the mitochondrial adaptor IFN-β promoter stimulator (IPS)-1, leading to 
activation of the transcription factors nuclear factor (NF)-κB and interferon regulatory 
factor 3 (IRF3) (Kang et al., 2002; Kawai et al., 2005). 5'-triphosphate RNAs are 
ligands for RIG-I. Therefore the EBERs, as 5'-triphosphate RNA molecules, could 
also interact with RIG-I (Hornung et al., 2006). Further studies found that EBER 
promotes BL cell growth by inducing expression of anti-inflammatory and growth-
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promoting cytokine IL-10, which is dependent on RIG-I-mediated IRF3 signaling. 
These results suggested that EBER-mediated RIG-I activation contributes to EBV 
oncogenesis (Samanta et al., 2006; Samanta et al., 2008).  
The AU-rich element-binding factor 1 (AUF1) has the ability to bind to AU-rich 
elements present in the 3'-untranslated regions of precursor RNA (Lu et al., 2006). 
The interaction between AUF1 and pre-mRNAs in the nucleus was reported to 
influence pre-mRNA processing, metabolism, and transport (Gratacos and Brewer, 
2010), whereas AUF1 alone might contribute to stabilize certain transcripts (Lal et al., 
2004). A recent paper demonstrated that AUF1 is a novel EBER1 binding protein as 
shown in Table 1.4. The EBER1/AUF1 interaction prevents AUF1 from binding to 
short-lived mRNAs (Lee et al., 2012). How this interaction might regulate the 
expression of EBV genes remains unclear. More recently, Lee et al demonstrated that 
EBER2 interacts with the B cell transcription factor PAX5 and is required for the 
localization of PAX5 to the terminal repeats (TRs) of the virus. Indeed, EBER2 and 
TR have partially complementary sequences that allow their interaction. EBER2 
knockdown phenocopies a PAX5 depletion in upregulating the transcription of 
LMP2A/B and LMP1, the genes located nearest to the TRs. Knockdown of EBER2 
also decreases EBV lytic replication, suggesting the essential role of the TRs in this 
process. Recruitment of the EBER2-PAX5 complex is mediated by base pairing 
between EBER2 and nascent transcripts from the TR locus. The interaction is 
evolutionarily conserved in the related primate herpesvirus CeHV15 despite great 
sequence divergence (Lee et al., 2015). To identify the interaction proteins between 
EBER2 and PAX5, the authors isolated EBER2-PAX5-containing complexes and 
analyzed the protein components by mass spectrometry. The top candidates include 
three host proteins splicing factor proline and glutamine rich (SFPQ), non-POU 
	 29	
domain-containing octamer-binding protein (NONO), and RNA binding motif protein 
14 (RBM14), all reported to be components of nuclear bodies called paraspeckles. It 
remains unknown whether SFPQ, NONO, and RBM14 are likewise essential for viral 
lytic replication. Intriguingly, these proteins also play a role in the life cycle of HIV 
(Budhiraja et al., 2015; Kula et al., 2013; Zolotukhin et al., 2003), suggesting a more 
common involvement of these factors in viral regulation. Detailed studies of these 
RRM-containing proteins are complicated by the fact that all three proteins function 
in multiple cellular processes, including transcription regulation, paraspeckle 
formation, and notably alternative splicing (Amelio et al., 2007; Naganuma et al., 
2012; Rosonina et al., 2005). In vivo RNA–protein crosslinking indicates that SFPQ 
and RBM14 contact EBER2 directly. Binding studies using recombinant proteins 
demonstrate that SFPQ and NONO associate with PAX5, potentially bridging its 
interaction with EBER2. Similar to EBER2 or PAX5 depletion, knockdown of any of 
the three host RNA-binding proteins results in the up-regulation of viral LMP2A 
mRNA levels, supporting a physiologically relevant interaction of these newly 
identified factors with EBER2 and PAX5 (Lee et al., 2016).  
Table. 1.4 Summary of other interacting proteins with EBERs 
	
	
Interac(on	
Proteins	
Interac(on	with	EBER1	or	
EBER2	 Interac(on	sites	
Direct	or	indirect	
interac(on	 References	
AUF1	 EBER1	 unknown	 direct	 Lee	et	al.,	2012	
hnRNP	D	 EBER1	 unknown	 direct	 Lee	et	al.,	2012	
Pax5	 EBER2	 unknown	 indirect	 Lee	et	al.,	2015	
SFPQ	 EBER2	 unknown	 direct	 Lee	et	al.,	2016	
NONO	 EBER2	 unknown	 indirect	 Lee	et	al.,	2016	
RBM14	 EBER2	 unknown	 direct	 Lee	et	al.,	2016	
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1.3.6 EBERs-mediated pathogenesis via modulation of innate 
immune signals   
Interactions between EBERs and host dsRNA sensors have been demonstrated to play 
an important role in EBV-mediated pathogenesis (Fig. 1.8). Samanta et al.  reported 
that EBER, which forms dsRNA structures, activates RIG-mediated signaling. The 
results suggest that in BL cells, RIG-I is activated by EBERs, resulting in the 
activation of NF-κB and IRF-3 pathways, and subsequent induction of type-I IFN. 
Although induction of IFN appears to be disadvantageous for the virus, EBV still can 
maintain a latent infection due to resistance to IFN, such as that provided by EBER-
mediated PKR inhibition (Nanbo et al., 2002). EBER promotes BL cell growth by 
inducing expression of the anti-inflammatory and growth-promoting cytokine IL-10, 
which is dependent on RIG-I-mediated IRF3 signaling but independent of NF-κB 
(Samanta et al., 2008).  
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Figure. 1.8 EBER-mediated regulation of innate immune signaling contributes to 
EBV-mediated pathogenesis. Reproduced from Iwakiri et al. Left, in BL cells, 
EBERs are recognized by RIG-I via the RNA helicase domain of RIG-I. Following 
recognition, RIG-I associates with the adaptor IPS-1 protein via its CARD domain. 
IPS-1 initiates signaling that leads to the activation of IRF3 and NF-κB to induce type 
I IFNs and inflammatory cytokine expression. EBERs induce the expression of the 
growth-promoting cytokine IL-10 via RIG-I-mediated IRF3 activation and might 
support BL development. EBERs also bind to IFN-inducible PKR and block its 
activity, which is required for the IFN-mediated antiviral effect. Right, activation of 
innate immunity via TLR3 signaling in response to secreted EBER. During an active 
EBV-infection, EBER1 is released from EBV-infected lymphocytes mainly in a 
complex with La. Circulating EBER induces DC maturation via TLR3 signaling and 
induces type I IFN and inflammatory cytokine production by activating IRF3 and NF-
κB. DC activation leads to T cell activation and systemic cytokine release. 
Furthermore, TLR3-expressing T and NK cells including EBV-infected T or NK cells 
could be activated by EBER1 through TLR3, thus leading to inflammatory cytokine 
production. Therefore, immunopathologic diseases caused by active EBV infections 
including T or NK cell activation and hypercytokinemia, could be attributed to 
EBER1-induced TLR3-mediated T cell activation and cytokinemia. IPS-1, interferon-
β promoter stimulator-1; CARD, caspase recruitment domain; RIG-I, retinoic acid-
inducible gene I; DC, dendritic cell; IFN, interferon; NK cell, natural killer cell; IL, 
interleukin; TLR, Toll-like receptor; PKR, RNA-dependent protein kinase; IRF 3, 
interferon regulatory factor 3.  
Toll-like receptors (TLRs) comprise a distinct family of PRRs that sense virus-
derived nucleic acids and trigger antiviral innate immune responses by activating 
signaling cascades via Toll/IL-1 receptor (TIR) domain-containing adaptors (Akira 
and Takeda, 2004). The role of TLR3 in the dsRNA recognition was demonstrated in 
a study of TLR3-deficient mice (Alexopoulou et al., 2001). DsRNA-induced signal 
transduction via TLR3 leads to the recruitment of TIR domain-containing adaptor 
inducing IFN-β (TRIF) and the subsequent phosphorylation of downstream molecules 
such as IRF3 and NF-κB (Meylan and Tschopp, 2006). Iwakiri et al. demonstrated 
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that EBERs are released in the extracellular environment and are recognized by 
TLR3, leading to the induction of type I IFN and inflammatory cytokines. The 
majority of the released EBER1 exists as a complex with La, suggesting that EBER1 
is released from the cells via the active secretion of La. EBV causes infectious 
diseases such as infectious mononucleosis (IM), chronic active EBV infection 
(CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). 
IM is characterized by the expansion of reactive T-cells and is most likely an 
immunopathologic disease, in which the general symptoms are caused by 
inflammatory cytokines (Rickinson, 2007). CAEBV and EBV-HLH are active EBV 
infections with persistent or recurrent IM-like symptoms. EBV-HLH is characterized 
by an EBV infection of  CD4-positive T cells or natural killer (NK) cells and the 
systemic release of inflammatory cytokines, leading to blood cell hemophagocytosis 
via activation of macrophages (Kasahara et al., 2001; Kikuta et al., 1993). On the 
other hand, in CAEBV, CD8+-T cells are primary EBV infection targets (Kasahara et 
al., 2001). Iwakiri et al. demonstrated that sera from patients with IM, CAEBV and 
EBV-HLH contained EBER1. A further analysis revealed that serum EBER1 
activates TLR3 signaling in immune cells, including dendritic cells, suggesting that 
EBER1, which is released from EBV-infected cells, is responsible for EBV-mediated 
immune activation, and induction of type I IFN and inflammatory cytokines (Iwakiri 
et al., 2009). Because CD8+-T cells and NK cells express TLR3 and can be activated 
by TLR3 signaling (Schmidt et al., 2004; Tabiasco et al., 2006), TLR3-expressing T 
and NK cells could potentially be activated by EBER1 through TLR3 to produce 
inflammatory cytokines. Therefore, EBER1-induced activation of innate immunity 
would account for the immunopathologic diseases caused by an active EBV infection. 
A more recent study of a humanized mice model of an EBV-infectious disease 
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detected EBER1 in the serum, thus suggesting that EBER1 contribute to the disease 
pathology (Sato et al., 2011). In summary, EBERs contribute to EBV infection-related 
pathogenesis, including cancer and active infectious diseases, through interactions 
with RIG-I and TLR3 (Iwakiri and Takada, 2010).  
1.3.7 Oncogenic role of EBERs 
EBERs have been reported to contribute to the malignant phenotype of BL cells.  
Transfection of EBER genes into EBV-negative BL-derived Akata clones can restore 
the cell growth capacity in soft agar, promote tumor formation in severe combined 
immunodeficiency (SCID) mice, confer resistance to apoptotic inducers, and also 
upregulate the expression of anti-apoptotic bcl-2 protein that could protect Akata cells 
from c-Myc induced apoptosis (Komano et al., 1999; Ruf et al., 2000). Previous 
results have confirmed that EBERs can induce various cytokines expression. EBERs 
induce human IL-10 expression in BL cells (Kitagawa et al., 2000)(Kitagawa et al., 
2000). Moreover, IL-10 is consistently expressed in EBV-positive but not in EBV-
negative BL biopsies. Further analysis showed that IL-10 acts as an autocrine growth 
factor for BL cells, suggesting that EBERs play a role in BL development via IL-10 
induction (Kitagawa et al., 2000). Additionally, EBERs were reported to contribute to 
the induction of IL-9, which also acts as an autocrine growth factor for T cell 
proliferation, suggesting that EBERs affect the development of EBV-associated T cell 
lymphoma (Yang et al., 2004). Furthermore, the EBERs have been demonstrated to 
contribute to the growth and proliferation of epithelial cell lines derived from NPC 
and GC. Iwakiri et al. demonstrated that EBERs could induce the expression of IGF1, 
which acts as an autocrine growth factor for NPC and GC cells. Further, IGF1 was 
expressed at high levels in EBV-positive but not in EBV-negative NPC or GC 
biopsies, indicating that EBERs promote epithelial carcinogenesis by the induction of 
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IGF1 expression (Iwakiri et al., 2003; Iwakiri et al., 2005). To determine the role of 
EBERs in the EBV-induced B cell growth program, recombinant EBV strains lacking 
EBERs have been engineered and introduced into host B-lymphocytes. However, 
conflicting observations regarding possible effects on B cell growth and 
transformation have been reported. An early study demonstrated that EBERs played 
no key role in infection with the EBV P3HR-1 strain, viral replication, or B-
lymphocyte growth transformation (Swaminathan et al., 1991). However, another 
study reported that the 50% transforming dose of an EBER-deleted Akata virus was 
approximately 100-fold lower than that of the EBER-positive wild type EBV (Yajima 
et al., 2005); Subsequently, EBER2 was found to make positive contributions to an 
efficient LCL growth transformation via the induction of IL-6 expression (Wu et al., 
2007). More recently, EBER deletion was reported to have no effect on LCL growth 
transformation efficiency of the B95-8 EBV strain (Gregorovic et al., 2011). It is 
important to note that all these results were obtained with different EBV strains. Thus, 
these discrepancies might be due to differences in the EBV strain background used in 
these experiments. We investigated the role of EBERs in the EBV strain M81 that 
was derived from NPC. Owing to the ability of M81 to induce spontaneous lytic virus 
replication, this model allows the study of the role of EBV-encoded small RNAs 
(EBERs) during this process.  
The EBERs were previously shown to be dispensable for lytic replication 
(Swaminathan et al., 1991), suggesting that they exert their functions during latency. 
Furthermore, deletion of EBER1 or EBER2 individually in EBV B95-8 correlates 
with specific gene expression changes in LCLs. The EBER-related genes play 
important roles in membrane signaling, regulation of apoptosis, and interferon 
responses (Gregorovic et al., 2011). Consistent with these data, the EBERs can 
	 35	
protect EBV-infected BL cells from interferon alpha-induced apoptosis (Nanbo et al., 
2002; Ruf et al., 2005).  
Further insights into EBER function may come from the unique secondary structures 
adopted by these two RNAs, that can facilitate interactions with host proteins. A 
number of cellular proteins are known to interact with the EBERs to form 
ribonucleoprotein complexes as described above. EBER2 may provide additional 
structured RNA elements for binding to other as yet undefined host factors. Indeed, 
new studies demonstrate interactions between EBER2, the EBV terminal repeats, and 
the B cell transcription factor PAX5 that can mediate LMP expression (Lee et al., 
2015). More recently, Zhao et al. analyzed a large number of samples from Northern 
China, a non-NPC endemic area and found that the distribution of EBER subtypes in 
lymphoma samples was similar to that in EBV-associated gastric carcinoma 
(EBVaGC) and throat washing (TW) from healthy donors, but was significantly 
different from that of NPC, suggesting that the NPC carry its unique EBERs which 
might have different functions. The distributions of EBER subtypes in samples used 
in this study are shown in Table. 1.5 and the location of EBER2 polymorphism is 
shown in Table. 1.6 (Zhao et al., 2017).  
 
Table. 1.5 Distribution of EBER subtypes in lymphoma, NPC, EBVaGC and TW 
    
	 36	
Table. 1.6 Location of the EBERs polymorphism 
   
Numbers in the second row correspond to the nucleotide positions, under which the 
prototypic (B95-8) nucleotide sequence is listed. Here we use “+1” to represent the 
first nucleotide position of the EBER2 transcript. In the upstream of the EBER2 
transcript, we use negative values to define the nucleotide position as shown before.  
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1.4 Animal study 
EBV can only infect human and primates. EBV cannot infect commonly used rodent 
species at all. This makes the in vivo study of EBV very difficult. In this study, we 
inject virus infected fresh B cells intraperitoneally into NSG mice (NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ; NSG). This mouse model simulates the post-transplant 
lymphoproliferative disease (PTLD) in patients infected with EBV. In most cases, 
PTLD is associated with Epstein-Barr virus (EBV) infection of B cells, either as a 
consequence of reactivation of the virus post-transplantation or from primary EBV 
infection. The majority of the PTLD patients display a deficiency in the immune 
system.  
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1.5 Aim of the thesis 
The EBV EBERs have been shown to play an important role during the viral life 
cycle. However, the literature contains conflicting results about their functions and 
their contribution to tumorigenesis. These discrepancies could be due to the use of 
different EBV strains that carry polymorphism in the EBERs.  
Therefore, the aim of my thesis was: 
• To construct recombinant viruses from two different EBV strains B95-8 and 
M81 that lack the EBERs. 
• To understand the contribution of the EBERs in these two different viruses. 
• To unravel the role of polymorphisms in the function of EBERs.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Eukaryotic cells 
Name	 Description	
	 	 	 	 	HEK293		 A	specific	cell	line	originally	derived	from	human	embryonic	
kidney	cells	
B	lymphocytes	 Primary	B	cells	isolated	from	blood	samples	
	 	WI38	 Primary	human	lung	embryonic	fibroblasts	
	 		
2.1.2 Primary cells 
Name Description 
Peripheral blood 
CD19+ cells 
Isolated from fresh buffy coats by Ficoll density gradient 
followed by selection with anti-CD19 PanB Dynabeads 
and detachment of the beads (Invitrogen) 
Primary epithelial 
cells 
Isolated from normal sphenoidal sinus biopsy material 
License to use human 
primary cells  
The Ethics Committee of the Universtiy of Heidelberg 
approved the study (approval 392/2005) 
	
2.1.3 Cell culture media 
Name  Source of supply 
RPMI 1640 Invitrogen 
 DMEM Life Technologies 
Fetal calf serum 
(FCS) 
Biochrom AG 
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2.1.4 Plasmids 
2.1.4.1 Vector plasmid 
Name Source of supply, description 
pcDNA3.1 This expression plasmid contains a CMV promoter.  
pRK5 This expression plasmid also contains a CMV promoter.  
B1249 B1249 (empty plasmid) contains a minimal CMV promoter 
controlled by a bidirectional Tet operator, a tetracycline 
transactivator protein (Tet-On) driven by a chicken beta-actin 
promoter with CMV enhancer (CAGp). One site of this 
bidirectional promoter contains the human neuron groewth 
factor receptor gene (NGFR) with a truncated cytoplasmic tail 
and GFP (Bornkamm et al., 2005). The other site is available for 
cloning. This plasmid also contains the latent EBV origin of 
replication (OriP) derived from B95-8 genome, and a rat CD2 
gene derived by the hPGK promoter. 
	
2.1.4.2 Expression plasmids 
Name Vector Description 
p509 pRK5 BZLF1 gene derived from B95-8 controled by a CMV 
promoter 
pRA pRK5 BALF4 (=gp110=gB) gene derived from B95-8, This plasmid 
will be co-transfected with BZLF1 to increase the B cells 
infectivity  
B1460 B1249 Co-expression of NGFR gene and EBER1 and EBER2 (4 
copies) derived from M81; controlled by a tetracycline 
inducible promoter 
B1510 B1249 Co-expression of NGFR gene and EBER1 and EBER2 (4 
copies) derived from B95-8; controlled by a tetracycline 
inducible promoter 
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2.1.5 Recombinant EBVs (rEBV; EBV-BAC) 
Name  
EBV 
strains/Backbone Source of supply, description 
B240 M81 M81 strain wild type  
B996 M81/B240 M81 strain wild type EBER1 deletion 
B997 M81/B240 M81 strain wild type EBER2 deletion 
B963 M81/B240 M81 strain wild type both EBER1 and EBER2 
deletion 
B893 M81/B240 Revertant of M81 strain wild type both EBER1 
and EBER2 deletion 
B1468 M81/B240 M81 strain wild type that carry both EBER1 
and EBER2 from B95-8 
B95-8 B95-8/2089 B95-8 strain wild type  
B222 B95-8/2089 B95-8 strain wild type both EBER1 and 
EBER2 deletion 
B1465 B95-8/2089 B95-8 strain wild type that carry both EBER1 
and EBER2 from M81  
	
2.1.6 Plasmids used for constructing recombinant EBV 
	
Name Purpose Description 
pCP15 Template of 
kanamycin 
This vector carries a region of homology with 
the EBV genome in which the kanamycin 
cassette can be inserted 
pCP16 Template of 
tetracycline 
This vector carries a region of homology with 
the EBV genome in which the tetracycline 
cassette can be inserted 
pKD46 Red recombinase 
expression  
This vector contains an Arabinose-inducible Red 
recombinase, which is used for homologous 
recombination in E.coli.  
pCP20 Encoding the FLP 
recombinase 
This plasmid shows temperature sensitive 
replication and thermal induction of FLP  
synthesis.  
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2.1.7 Antibodies 
Name Clone Usage Origin Source of supply 
Anti-alpha-actin ACTN05, 
C4 
WB Mouse, 
momoclonal 
Dianova 
Anti-mouse lgG  
(HRP, secondary  
antibody) 
WB Goat Promega 
Anti-rabbit lgG  
(HRP, secondary 
 antibody) 
WB Goat Cell Signaling 
Anti-rat lgG  
(HRP, secondary  
antibody) 
WB Goat Dianova 
EBNA1 IH4 WB Rat Hybridoma supernatant 
EBNA2 PE2 WB, IHC  Mouse Hybridoma supernatant 
EBNA3A 4A5 WB Rat Hybridoma supernatant 
EBNA3B 6C9 WB Rat Hybridoma supernatant 
EBNA3C A10 WB Rat Hybridoma supernatant 
LMP1 CS1-4 WB, IHC  Mouse Hybridoma supernatant 
LMP2A 4E11 WB Rat 2089 LCL 
BZLF1 BZ.1 WB, IHC  Mouse Hybridoma supernatant 
gp350 72A1 IF Mouse Hybridoma supernatant 
NGFR  IF, cell 
isolation 
Mouse  
CD63 MX-
49.129.5,  
WB Mouse Santa Cruz 
	
2.1.8 Enzymes 
Name Company Usage 
Phusion High-Fidelity DANN 
polymerase 
Thermo Scienfitic PCR for cloning 
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Restriction Enzymes Fermentas, New 
England Biolabs 
Check genomic interity of 
EBV-BAC 
Alkaline Phosphatase Roche Cloning 
Klenow Enzyme Roche Cloning 
T4 DNA Polymerase Fermentas Cloning 
RNase A Roche Mini/Midi-pepe 
Lysozyme Serva mini-prep 
DNaseI Fermentas qPCR 
Proteinase K  Roche Viral titer measurement 
AMV Reverse Transcriptase Roche qPCR 
RNAse inhibitor Roche qPCR 
T4 DNA Ligase Fermentas Cloning 
Taqman Universal Master Mix Life technologies qPCR 
	
2.1.9 Commercial Kits 
Name	 Company	 Usage	in	this	study	
Dneasy	blood&Tissue	kit	 Qiagen	 Isolation	of	total	DANN	
from	cells	
Dynabeads	CD19	PanB		 Invitrogen	 Human	primary	B	cells		
isolation	
Dynabeads	Goat	anti	
mouse	lgG	
Invitrogen	 Cell	isolation	
Hygromycin	B	 Invitrogen	 Stable	cell	selection	
MicroRNA	reverse	
transcript	
Applied	Biosystems	 RT-PCR	
RNU48	 Applied	Biosystems	 Internal	controls	for	miRNA			
RT-qPCR	
Nucleobond	BAC100	 Macherer-Nagel	 EBV-BAC	preparation	
Jestar	2.0	Plasmid	Midi	Kit	 Genomed	 High	quality	DNA		
Preparation	
hGAPDH	endogeous	 Applied	Biosystems	 Internal	controls	for	RT-	
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control	
Human	IL-8	(CXCL8)	ELISA	
development	kit	
Total	Exosome	Isolation	
(from	cell	culture	media)	
	
Mabtech	
	
Invitrogen	
qPCR	
CXCL8	measurement	
	
Exosomes	isolation	
	
2.1.10 Equipment 
Name Source of supply 
Amersham HyperfilmTM ECL Stratagene 
Amersham membrane HybondTM ECL GE Healthcare Life Sciences 
Applied Biosystems 7300 Real-time PCR UVP 
D-Tube Dialyzer Midi, cutoff 3.5kDa Merck Millipore 
G25 Microspin columns Thermo Scientific 
Magnetic rack Applied Biosystems  
Nanodrop GE Healthcare Life Sciences 
	
2.1.11 Chemicals and Reagents 
Name Source of supply 
RNase inhibitor (RNasin) Promega 
Protease inhibitor cocktail Roche 
Acrylamide: 30% stock, with 0-8% 
bisacrylamide 
Roche 
Page Ruler Prestained Protein Ladder Fermentas 
1 kb DNA Ladder Life Technologies 
Taqman microRNA Reverse Transcription Kit Applied Biosystems 
TRIzol reagent Life Technologies 
Chloroform Sigma aldrich 
Phenol/Chloroform/Isoamylalcohol Roth 
Roti-Phenol Roth 
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RNase free water Invitrogen 
3 M sodium acetate, pH 5.5, Rnase free Invitrogen 
GlycoBlue Invitrogen 
Isopropanol Sigma aldrich 
Ethidium bromide Life Technologies 
dNTP mix (10mM) Invitrogen 
Metafectene  Biontex Laboratories 
6x DNA loading dye Thermo Scientific 
	
2.1.12 Buffers and solutions 
Buffer Composition 
Antigen binding and 
washing 
PBS+0.1% Tween 20 
Citrate-phosphate 
buffer 
4.7g/L citric acid, 9.2g/L Na2HPO4, pH 5.0 
SDS loading buffer 100mM Tris-HCl pH=6.8, 4% (w/v) SDS (electrophoresis 
grade), 0.2% (w/v) bromphenol blue, 20% (v/v) glycerol, 
200mM ß-merapto-Ethonal 
5x RIPA lysis buffer 750mM NaCl, 2.5% NP40, 5% Sodium Deoxycholat, 0.5% 
SDS, 25mM EDTA, 100mM Tris HCl pH=7.5 
DNA gel extraction 
buffer 
300mM NaCl, 10mM Tris (pH 8.0), 1mM EDTA 
Stacking gel buffer 2M Tris pH 6.8 
Seperating gel buffer 2M Tris pH 8.9 
10x SDS running buffer 250mM Tris, 1.92M glycine, 1% SDS, pH 8.5-8.8 
2x SDS loading buffer 100mM Tris-HCl pH=6.8, 4% (w/v) SDS (electrophoresis 
grade), 0.2% (w/v) bromphenol blue, 20% (v/v) glycerol, 
200mM ß-merapto-Ethonal 
1x bloting buffer 25mM Tris, 150mM glycine, 10% MetOH 
10x PBST 1.37M Nacl, 27mM KCl, 100mM Na2HPO4, 20mM 
KH2PO4, 1% Tween 20 
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3% low fat milk 3% low-fat milk power in 1xPBST 
ECL reagents Enhanced Luminol Reagent and Oxidizing Reagent, store at 
4°C 
PBS 137mM Nacl, 2.7mM KCl, 10mM Na2HPO4, 2mM 
KH2PO4, pH 7.4 
PBS-T 0.1% Tween-20 in PBS 
TAE 40mM Tris, 1mM EDTA, 19mM acetic acid 
TBE  100mM Tris, 90mM boric acid, 1mM EDTA 
Lysis buffer (circle 
prep) 
1% SDS, 2mM EDTA, 50mM NaCl, 40mM NaOH 
DNA loading buffer 0.25% Bromphenolblue, 40% (w/v) Sucrose, dissolved in 
H2O 
TE 10mM Tris.HCl, 1mM EDTA (pH 8.0) 
LB medium (2:1:2) Tryptone, Yeast extract, NaCl in H2O pH7.0 
LB agar 15g Bacto-Agar in 1L LB mudium 
4% PFA 4% Paraformaldehyde in PBS (pH 7.4) 
Staining buffer (IF) 10% Heat-inactivated goat serum in PBS 
Mounting buffer (IF) 90& Glycerol in PBS 
	
2.1.13 Oligonucleotides 
Oligonucleotides were synthesized by Eurofins, if not indicated otherwise. All 
oligonucleotides uses in this study and their sequences are listed below. 
Name Sequence Aim 
EBER1 fwd 
5'-
gtcttgaggagatgtagacttgtagacactgcaaaacctcaacagctatga
ccatgattacgcc-3' M81/∆E1 
cloning 
EBER1 rev 
5'-
ggataatggatgcataaatcctaaaacaaaagtttggatcccagtcacgac
gttgtaaaacgac-3' 
EBER2 fwd 
5'-
tttaccagcatgtatagagttacggttcgctacatcaaacaacagctatgac
catgattacgcc-3' M81/∆E2 
cloning 
EBER2 rev 
5'-
tttaccagcatgtatagagttacggttcgctacatcaaacaacagctatgac
catgattacgcc-3' 
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EBER1+2 fwd 
5'-
gtcttgaggagatgtagacttgtagacactgcaaaacctcaacagctatga
ccatgattacgcc-3' M81/∆E1+2 
cloning  
EBER1+2 rev 
5'-
tttaccagcatgtatagagttacggttcgctacatcaaacaacagctatgac
catgattacgcc-3' 
EBER1+2 fwd 
5'-
gtcttgaggagatgtagacttgtagacactgcaaaacctcaacagctatga
ccatgattacgcc-3' B95-8/∆E1+2 
cloning 
EBER1+2 rev 
5'-
tttaccagcatgtatagagttacggttcgctacatcaaacaacagctatgac
catgattacgcc-3' 
EBERseq_fwd 5'-acacaccaactatagcaaacc-3' Cloning of the 
M81/∆E1+2 
revertant  EBERseq_rev 5'-ttttgtgttgtaggggtagc-3' 
EBER SceI EP 
fwd 
5'-
tttcatcctcaggacctacgctgccctagaggttttgctagggaggcttcaa
gatccccgatctatgattccc-3' 
Cloning of the 
∆E1+2 
revertant -put 
I-sceI enzyme 
restriction sites  
EBER SceI EP 
rev 
5'-
tttcatcctgaggtagggataacagggtaatcagagcgcttttgaagctcc
ag-3' 
EBER1 probe 5'FAM-aggacggtgtctgtggttgt-3'TAMRA RT-qPCR for 
Taqman  EBER1 fwd 5’-acgctgccctagaggttttg-3’ EBER1 rev 5’-gcagaaagcagagtctggga-3’ 
EBER2 probe 5'FAM-tcccgcctagagcatttgcaa-3'TAMRA RT-qPCR for 
Taqman EBER2 fwd 5’-gttgccctagtggtttcgga-3’ EBER2 rev 5’-gccgaatacccttctcccag-3’ 
M81.EBNA2 
probe 5'FAM-cccaaccacaggttcaggcaaaacttt-3'TAMRA 
RT-qPCR for 
Taqman 
M81.EBNA2 
fwd 5'-gcttagccagtaacccagcact-3' 
M81.EBNA2 
rev 5'-tgcttagaaggttgttggcatg-3' 
M81.LMP1 
probe 5'FAM-tgctgttcatctttggctgc-3'TAMRA 
RT-qPCR for 
Taqman 
M81.LMP1 
fwd 5'-cacggacaggcattgtacct-3' 
M81.LMP1 
rev 5'-ggatgaaggccaaaagctgc-3' 
M81.LMP2A 
probe 5'FAM-cagtatgcctgcctgtaattgttgcgc-3'TAMRA 
RT-qPCR for 
Taqman 
M81.LMP2A 
fwd 5'-cgggatgactcatctcaacacata-3' 
M81.LMP2A 
rev 5'-ggcgctgacaacggtactaact-3' 
M81.LMP2B 
probe 5'FAM-cagtatgcctgcctgtaattgttgcgc-3'TAMRA 
 
RT-qPCR for 
Taqman 
 
M81.LMP2B 
fwd 5'-cgggaggctgtgcttta-3' 
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M81.LMP2B 
rev 5'-ggcgctgacaacggtactaact-3' 
 
B95-8.LMP1 
probe 
5'FAM-tccagatacctaagacaagtaagcacccgaagat-
3'TAMRA 
RT-qPCR for 
Taqman 
B95-8.LMP1 
fwd 5'-gcacggacaggcattgttc-3' 
B95-8.LMP1 
rev 5'-aaggccaaaagctgccagat-3' 
B95-8.LMP2A 
probe 5'FAM-cagtatgcctgcctgtaattgttgcgc-3'TAMRA 
RT-qPCR for 
Taqman 
B95-8.LMP2A 
fwd 5'-cgggatgactcatctcaacacata-3' 
B95-8.LMP2A 
rev 5'-ggcggtcacaacggtactaact-3' 
B95-8.LMP2B 
probe 5'FAM-cagtatgcctgcctgtaattgttgcgc-3'TAMRA 
RT-qPCR for 
Taqman 
B95-8.LMP2B 
fwd 5'-cgggaggccgtgcttta-3' 
B95-8.LMP2B 
rev 5'-ggcggtcacaacggtactaact-3' 
RN7SK probe 5'FAM-gttgattcggctgatctggctg-3'TAMRA RT-qPCR for 
Taqman RN7SK fwd 5'-tctgtcaccccattgatcgc-3' RN7SK rev 5'-ttggaggttctagcagggga-3' 
EBV-pol fwd 5'-ctttggcgcggatcctc-3' 
Quantification 
of viral titers 
EBV-pol rev 5'-agtccttcttggctagtctgttgac-3' 
EBV-pol 
probe 5'FAM-catcaagaagctgctggcggcc-3'TAMRA 
BART 1-3p 
RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgagagacatag-3' 
Stem-loop RT-
qPCR BART 
1-3p Taqman 
PCR 
BART 1-3p 
fwd 5'-acactccagctgggtagcaccgctatccac-3' 
BART 1-3p 
probe 5'FAM-ttcagttgagagacatag-3'TAMRA  
BART 1-3p 
rev 5'-ctcaactggtgtcgtggagtcggca-3' 
BART 7* RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgagtgtttcat-3' Stem-loop RT-
qPCR BART 
7* Taqman 
PCR 
BART 7* fwd 5'-acactccagctgggcctggaccttgactat-3' 
BART 7* 
probe 5'FAM-ttcagttgagtgtttcat-3'TAMRA  
BART 7* rev 5'-ctcaactggtgtcgtggagtcggca-3' 
BART 2-5p 
RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgaggcaagggc-3' 
Stem-loop RT-
qPCR BART 
2-5p Taqman 
PCR 
BART 2-5p 
fwd 5'-acactccagctgggtattttctgcattcgc-3' 
BART 2-5p 
probe 5'FAM-ttcagttgaggcaagggc-3'TAMRA  
BART 2-5p 
rev 5'-ctcaactggtgtcgtggagtcggca-3' 
BHRF 1-1 RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgagaactccgg-3' Stem-loop RT-
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BHRF 1-1 fwd 5'-acactccagctgggtaacctgatcagcccc-3' qPCR BHRF1 
miR1 
Taqman PCR 
BHRF 1-1 
probe 5'FAM-ttcagttgagaactccgg-3'TAMRA 
BHRF 1-1 rev 5'-ctcaactggtgtcgtggagtcggca-3' 
BHRF 1-2 RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgagttcaattt-3' Stem-loop RT-
qPCR  BHRF1 
miR2 
Taqman PCR 
BHRF 1-2 fwd 5'-acactccagctgggtatcttttgcggcaga-3' 
BHRF 1-2 
probe 5'FAM-ttcagttgagttcaattt-3'TAMRA 
BHRF 1-2 rev 5'-ctcaactggtgtcgtggagtcggca-3' 
BHRF 1-2* 
RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgaggctatctg-3' 
Stem-loop RT-
qPCR  BHRF1 
miR2* 
Taqman PCR 
BHRF 1-2* 
fwd 5'-acactccagctgggaaattctgttgcagca-3' 
BHRF 1-2* 
probe 5'FAM-ttcagttgaggctatctg-3'TAMRA 
BHRF 1-2* 
rev 5'-ctcaactggtgtcgtggagtcggca-3' 
BHRF 1-3 RT 5'-ctcaactggtgtcgtggagtcggcaattcagttgaggtgtgctt-3' Stem-loop RT-
qPCR BHRF1 
miR3 
Taqman PCR 
BHRF 1-3 fwd 5'-acactccagctgggtaacgggaagtgtgta-3' 
BHRF 1-3 
probe 5'FAM-ttcagttgaggtgtgctt-3'TAMRA 
BHRF 1-3 rev 5'-ctcaactggtgtcgtggagtcggca-3' 
M81.BZLF1 
fwd 5’-acgacgtacaaggaaacc-3’ 
RT-qPCR for 
Taqman  
M81.BZLF1 
rev 5'-cttggcccggcattttct-3' 
M81.BZLF1 
probe 5'FAM-gcattcctccagcgattctggctgta-3'TAMRA 
GADPH fwd 5'-caatgaccccttcattgacc-3' 
SYBR green  
RT-qPCR  
GADPH rev 5'-tggaagatggtgatgggatt-3' 
CXCL8 fwd 5'-tctgcagctctgtgtgaagg-3' 
CXCL8 rev 5'-ttccttggggtccagacaga-3' 
T44G fwd 5'-ggacacaccgccaacgcgcagtgcggtgctaccgac-3' 
EBER2 
mutation in 
position 44 
T44G G44T 
A46T T46A 
rev 
5'-gaaaccactagggcaacggc-3' 
G44T fwd 5'-ggacacaccgccaacgctctgtgcggtgctgccgt-3' 
T44G G44T 
A46T T46A 
rev 
5'-gaaaccactagggcaacggc-3' 
A46T fwd 5'-ggacacaccgccaacgctctgtgcggtgctaccgaccc-3' 
EBER2 
mutation in 
position 46 
T44G G44T 
rev 5'-gaaaccactagggcaacggc-3' 
T46A fwd 5'-ggacacaccgccaacgcgcagtgcggtgctgccgtccc-3' 
T44G G44T 
rev 5'-gaaaccactagggcaacggc-3' 
A57G fwd 5'-caacgctcagtgcggtgctgccgacccgaggtcaagtc-3' EBER2 
mutation in 
position 57 
A57G G57A 
rev 5'-gcggtgtgtccgaaaccac-3' 
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G57A fwd 5'-caacgcgctgtgcggtgctaccgtcccgaggtcaagtc-3' 
A57G G57A 
rev 5'-gcggtgtgtccgaaaccac-3' 
A61T fwd 5'-tcagtgcggtgctaccgtcccgaggtcaagtcccg-3' 
EBER2 
mutation in 
position 61 
A61T T61A 
rev 5'-gcgttggcggtgtgtcc-3' 
T61A fwd 5'-gctgtgcggtgctgccgacccgaggtcaagtcccg-3' 
A61T T61A 
rev 5'-gcgttggcggtgtgtcc-3' 
A93C fwd 5'-ccgggggaggagaagagcggcttcccgcctagagc-3' EBER2 
mutation in 
position 93 
A93C rev 5'-gacttgacctcgggtcggtag-3' 
C93A fwd 5'-ccgggggaggagaagagaggcttcccgcctagagc-3' 
C93C rev 5'-gacttgacctcgggacggca-3' 
A168G fwd 5'-gggtattcggcttgtccgctgtttttttacgcgttaagatacattgatgag-3' 
EBER2 
mutation in 
position 168 
A168G 
G168A rev 5'-ttctcccagagggattagagaatcctg-3' 
G168A fwd 5'-gggtattcggcttgtccgctatttttacgcgttaagatacattgatgag-3' 
A168G 
G168A rev 5'-ttctcccagagggattagagaatcctg-3' 
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2.2 Methods 
2.2.1 Bacterial culture and transformation 
2.2.1.1 Culture conditions 
All E.coli strains were cultured in LB-medium by shaking or alternatively on LB-agar 
plates in order to obtain single colonies. Ampicillin (100 ug/ml), kanamycin (50 
ug/ml) or chloramphenicol (15 ug/ml) were used to culture cells in LB-medium or 
LB-agar plates, depending on the antibiotic resistance genes cloned into the plasmids.  
Except special conditions, bacteria were cultured at 37°C. For long-term storage, 10 
% glycerol was used to freeze cells at -80°C.  
 
2.2.1.2 Transformation 
The plasmids were introduced into bacteria by the heat shock method. In general, 
chemically competent cells (eg. DH5α) were mixed with plasmids or the ligation 
product on ice for 5 min. The mixture was then incubated at 42°C for 90 sec, 
immediately added to 900 ul of LB-medium and left in culture at 37°C for 45 min for 
recovery. After recovery, bacteria were spun down by centrifugation at 4800 rpm for 
5 min and the pelleted cells were resuspended and cultured on LB-agar plate 
overnight to obtain single colony.  
 
2.2.1.3 Electroporation 
Electroporation was also used to transform plasmids into electroporation-competent 
bacteria that were made by a technician. In general, 25 ul of electroporation-
competent DH10B cells pre-prepared in 10% glycerol were thawed slowly on ice 
from -80 °C.  The thawed cells were mixed with DNA and this mixture was incubated 
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on ice for 5 min. The mixture was transferred into cuvettes and subjected to 
electroporation at 1.2 KV, 200 Ω, and 25 µFd. The bacteria were then immediately 
resuspended in 1 ml of LB-medium and cultured at 37°C for 1 h. Individual colony 
was obtained in the same way as the heat shock method.  
 
2.2.2 Eukaryotic cells culture and transfection 
2.2.2.1 Culture conditions 
All eukaryotic cells were cultured at 37 °C in the incubator stably supplied with 100% 
humidity and 5% CO2. 
Cells that grow in suspension, including LCLs, were cultured in RPMI with 10% 
FBS. The cells were split 1 to 5 or 1 to 10 regularly, depending on their growth rate or 
state. 293 cells that grow adherently were cultured in RPMI with 10% FBS. 
Additional 100 µg/ml Hygromycin was used to culture 293 cells that stably 
transfected with the recombinant EBV. The 293 cells were split 1 to 10 by using 
0.05% trypsin at 37°C for 2 min when they reach about 80% confluence. WI 38 
feeder cells were cultured in the same condition except that 0.25% trypsin was used to 
split them.  
 
2.2.2.2 293 cells transfection 
The cells were seeded at a concentration of 3x 105 cells/well on a 6-well-plate in 2 ml 
RPMI with 10% FBS without any antibiotics one day before transfection. At day 2, 
the transfection mixture was prepared in the following procedure: 1 µg plasmid DNA 
was resuspended in 100 µl of RPMI w/o any additions and 3 µl of Metafectene was 
also resuspended with 100 µl of RPMI w/o any additions. These two mixtures were 
combined gently by carefully pipetting few times, and left for 25 min at room 
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temperature. The plasmid-Metafectene mixture was added dropwise into the cells, and 
the cells were incubated at 37°C overnight. At day 3, the medium of the transfected 
cells was carefully removed and replaced with 2 ml fresh medium RPMI with 10% 
FCS. The transfected cells can usually be analyzed 3 days post transfection.  
 
2.2.2.3 LCLs transfection 
We used Neon Transfection System to introduce plasmids into LCLs. The cells were 
washed with PBS without Ca2+ and Mg2+ three times and resuspended with buffer T, 
which is used for primary blood-derived suspension cells, at a final density of 2.0x 
107 cells/mL in a 1.5 mL tube. In parallel, an appropriate amount of plasmid DNA in 
deionized water at a concentration of 3-5 µg/µL was transferred into a 1.5 mL tube. 
The cells and plasmid DNA were combined gently by carefully pipetting few times. 
Then we performed the transfection following the manufacturer’s instructions. The 
mixture was subjected to electroporation at 1.1 KV of pulse voltage, 30 ms of pulse 
width and 2 of pulse number. The transfected cells can usually be analyzed 3 days 
post transfection.  
 
2.2.3 Construction of recombinant EBVs and related techniques 
The wild type EBV strain M81 is available as a recombinant BACMID (Tsai et al., 
2013). The viral genome was cloned onto a prokaryotic F-plasmid that carries the 
chloramphenicol (Cam) resistance gene, the gene for green fluorescent protein (GFP), 
and the Hygromycin resistance gene (B240). All PCR primers used for PCR cloning 
or chromosomal building are listed in the Table and are based on the M81 EBV 
sequence (GenBank accession number KF373730.1). Deletion of the EBER1 
(deletion from nt 6632 to nt 6797) generated ∆E1; deletion of the EBER2 (deletion 
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from nt 6959 to nt 7128) gave rise to ∆E2. The double knockout EBER1 plus EBER2 
(∆E1+2) was obtained by a deletion from nt 6632 to nt 7128 including the intergenic 
sequences between EBER1 and EBER2. These mutations were achieved by 
homologous recombination of the recombinant virus with a linear DNA fragment that 
encodes the kanamycin resistance gene, flanked by Flp recombination sites, and short 
DNA regions homologous to the regions immediately outside of the deletion to be 
obtained, as described (Feederle et al., 2010). We applied the same strategy to the 
wild type B95-8 BAC to obtain a recombinant EBV that lacks EBER1 plus EBER2 
(B95-8/∆E1+2) with a deletion from nt 6630 to nt 7128 including the intergenic 
region between EBER1 and EBER2. We constructed a revertant of ∆E1+2 in M81 
strain by using an En passant mutagenesis method. Here the complete EBER locus, 
from the EBER1 to EBER2, was cloned from the M81 BAC and reintroduced into the 
M81/∆E1+2 BAC genome. In parallel, we applied the same En passant method to 
construct an exchange mutant that carries EBER locus of B95-8 in M81 strain. Here 
the complete EBER locus, from the EBER1 to EBER2, was cloned from the B95-8 
BAC and reintroduced into the M81/∆E1+2 BAC genome. In addition, we also 
applied the same En passant method to construct an exchange mutant that carries 
EBER locus of M81 in B95-8 EBV strain.  
We introduced the rat CD2 gene under the control of an EA-D promoter into the 
BXLF1 gene of the M81 genome (nt 131044 to nt 133362) by homologous 
recombination using a linear vector that included the kanamycin resistance cassette as 
a selection marker. The disruption of BXLF1 gene does not interfere with the growth 
of LCLs (Kanda et al., 2004; Yoshiyama et al., 1995). Upon induction of the lytic 
replication, CD2 is expressed at the surface of replicating cells. CD2-positive cells 
can be pulled down with a specific monoclonal antibody (OX34) coupled with anti-
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mouse IgG Dynabeads and submitted to protein or RNA extraction. 
2.2.4 Generation of EBV/293 producer cells 
To generate HEK293 producer cells stably transfected with EBV, 6 or 8 µg BACmid 
was transfected into 293 cells at a concentration of 3x105 cells/well cultured in 6-well 
plate by using Metafectene following the manufacturer’s instructions. Transfection 
efficiency could be checked under microscope 24 hours post transfection by 
observing the percentage of GFP positive cells. The cells were transferred into 15 cm 
culture dishes in the presence of 100 µg/ml Hygromycin B in order to select 293 cells 
stably transfected with the recombinant EBV. Selected single cell clones were 
transferred to 6 well-plate around 3 weeks post transfection. The cells were expanded 
and tested for virus production by transient transfection of a plasmid encoding 
BZLF1, a viral protein that trans-activates lytic EBV replication. The BZLF1 
transfected clones were stained with antibody against gp350, the major viral 
glycoprotein 3,5 days post transfection. The supernatants of clones with a high signal 
of gp350 staining after BZLF1 transfection was measured by qPCR to determine the 
viral titer. The clones, which display the highest viral titer, were tested by circle 
preparation to determine their genome integrity in 293 producer cells (Lin et al., 
2015). 
2.2.5 Virus production 
After establishment of viral producer cell lines, these cells were continuously 
maintained with 100 µg/ml Hygromycin B selection in order to keep EBV BAC 
inside the cells in the long term. The 293 producer cell lines were lytically induced by 
transfection of a BZLF1 expression plasmid together with a BALF4 expression 
plasmid.  
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The medium of the transfected cells was carefully removed 16 hours post transfection 
and replaced with fresh medium RPMI with 10% FCS. Virus supernatant was 
harvested at 3.5 days post transfection, filtered with 0.45 µm cellulose filter and 
stored at 4 °C (Lin et al., 2015). 
2.2.6 Viral titers measurement by qPCR 
The viral genome copy number was determined by qPCR measurement. 50 µl of 
supernatants were firstly treated with 5 unit DNAseI at 37 °C for 1 h to completely 
remove free viral DNA in supernatants and DNAseI was then inactivated at 70 °C for 
10 min. In this way, the viral DNA inside the viral particles was not digested by 
DNAseI due to the protection from viral envelope. The viral envelope was then 
digested by proteinase K in order to release the vial genome for qPCR analysis. 5 µl 
of DNAseI treated supernatants were incubated with 5 µl of proteinase K (100 µg/ml) 
for 1 h at 50 °C. Proteinase K was destroyed at 75 °C for 20 min. The qPCR master 
mix with primers and probe specific for the viral DNA polymerase BALF5 gene was 
prepared, mixed with the proteinase K treated supernatants and amplified by real time 
PCR using a StepOnePlus device.  
An example is given below for a 25 µl reaction containing the following components: 
12.5 µL  Taqman 2x Universal Mastermix  
2.5 µL  EBV Pol for primer (10 µM) 
2.5 µL  EBV Pol rev primer (10 µM) 
1.0 µL  FAM-labeled EBV Pol probe (20 µM) 
1.5 µL  water 
+5.0 µL  Proteinase K treated samples 
25 µL in total  
The qPCR was run with the following settings: 
50 °C for 2 min (initial denaturation) 
95 °C for 10 min (denaturation) 
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40 cycles:  
95 °C for 15 s 
60 °C for 1 min 
The qPCR results were analyzed to get an abosulate copy number of EBV genomes 
per ml of viral supernatants by using a standard curve (This protocol is modified from 
the shared folder from F100, DKFZ). 
 
2.2.7 Confirmation of the genome integrity of rEBV in the stably 
transfected 293 cells by analyzing the rescued circular BACmid 
(circle prep) 
20 millions of 293 cells were washed in PBS for two times and lysed with circle prep 
lysis buffer at room temperature for exactly 5 min. 500 µl of 1 M Tris-HCl, pH 7.1  
were added into the solution dropwise to neutralize the pH of the lysate. 2 ml of 3 M 
NaCl were then added. Proteins in the lysate were incubated with proteinase K 
(10mg/ml) at 50 °C for 2 h or at 37°C overnight. In order to get a high quality circular 
DNA, a phenol/butanol extraction method was performed. DNA was precipated with 
2.5 volume of absolute ethonal for 1 h at -20 °C or overnight. DNA was pelleted 
down at 5.000 rpm for 30 min at romm temperature. DNA was washed with 70% 
ethonal twice and was dissolved in 50 µl TE. The TE-dissolved BAC DNA was 
transformed into E.coli DH10B and the BACmid from at least 5 cam-resistant 
colonies were prepared and subjected to digestion with the BamHI enzyme. The 
genome integrity of these rEBV in the stably transfected cells was confirmed by using 
the parental rEBV as a control (This protocol is modified from the shared folder from 
F100, DKFZ).   
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2.2.8 Virus infections 
Purified CD19+ human B cells from peripheral blood were exposed to viral 
supernatant with various multiplicity of infection (MOI), determined by qPCR, for 
two hours, then washed once with PBS and cultured with RPMI supplemented with 
20% FBS in the absence of immunosuppressive drugs. For transformation assays, the 
percentages of EBNA2-positive cells in the infected B cells were evaluated by 
immunostaining with a specific antibody at 3 days post-infection (dpi). Cell numbers 
containing 3 or 10 EBNA2-positive cells per well were seeded into 48 wells of 96-U-
well plates that contained 103 gamma-irradiated WI38 feeder cells. Non-infected B 
cells were used as a negative control. The outgrowth of LCLs was monitored at 30 dpi 
(Lin et al., 2015).  
2.2.9 ImmunofIuorescence staining  
The cells were fixed with 4% paraformaldehyde in PBS for 20 min at room 
temperature. Fixed cells were permeabilized in PBS 0.5% Triton X-100 for 2 min 
except for samples stained with an antibody specific for the viral glycoprotein gp350. 
Cells were incubated with the first antibody for 30 min at 37°C, washed in PBS three 
times, and incubated with a secondary antibody conjugated to Cy-3 for 30 min at 
37°C. The stained slides were embedded in 90% glycerol and stored at 4°C. Pictures 
were taken with a camera attached to a fluorescence microscope (Leica) (This 
protocol is modified from the shared folder from F100, DKFZ).  
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2.2.10 RNA extraction  
Total RNA was extracted from LCLs generated with multiple M81 EBV or M81 
mutant or control strains. RNA extracted from HEK293 cells was used as a negative 
control for the data analysis.  
RNA was isolated from each sample by using a TRIzol reagent. Cells pellet was 
lyzed with 1 ml TRIzol and extracted with 0.2 ml CHCl3. TRIzol lysate was 
shaked  
vigorously for at least 30 s at room temperature and then was incubated for 2 
mins. Samples were centrifuged at 4 °C, at 12000 g, for 15 mins (cold room). 
The upper colorless aqueous phase was carefully transferred into a new tube that 
containing 500 µl of 2-Propanol (iso-PrOH). Carefully mix by inverting the 
centrifuge tube and RNA was precipated at -20 °C for at least 20 mins. RNA was 
pelleted at 4°C, at 12000 g, for 10 mins (cold room). The supernatant was 
removed and the pellet was washed with 75% Ethanol (EtOH; prepared with 
nuclease-free water) and centrifuged at 4°C, at 8000 g, for 5 mins (cold room). 
The RNA pellet was resuspended in 40 µl of pre-heated nuclease-free water (95 
°C). To dissolve the RNA pellet completely, the samples were incubated at 60°C 
for 10 mins with vortex. RNA concentration was determined at OD260 nm in a 
nandrop photospectrometer. RNA was stored at -80°C (This protocol is modified 
from the shared folder from F100, DKFZ).  
 
2.2.11 Real-time qPCR  
Total RNA isolated from LCLs were reverse transcribed with AMV-reverse 
transcriptase (Roche) using a mix of random hexamers. 200 ng total RNA was used 
for reverse transcription.  
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An example is given below for a 20 µl reaction containing the following components: 
4 µl   5x RT buffer  
2 µl   2mM dNTPs  
2 µl   random hexamers 
4 µl   MgCl2 
0.8 µl   AMV reverse transcriptase 
1 µl  RNA inhibitor 
1.2 µl   water 
15 µl in total Mix 
5 µl of RNA sample was added to the master mix and incubated on ice for 5 minutes. 
The RT reaction was running following program:  
25 ˚C  10 min 
42 ˚C  60 min  
90˚C   5 min 
4˚C   hold 
Store final cDNA at –20 ˚C until required. Add 80 ul water and use 5ul per RT-PCR 
reaction.  
An example is given below for a 25 µl reaction containing the following components: 
12.5 µL  Taqman 2x Universal Mastermix  
6 µL  Primer/Probe mix   
0.5 µL  hGAPDH 
1 µL   water 
+5.0 µL  cDNA sample 
25 µL in total  
The qPCR was run with the following settings: 
50 °C for 2 min (initial denaturation) 
95 °C for 10 min (denaturation) 
40 cycles:  
95 °C for 15 s 
60 °C for 1 min 
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The qPCR results were analyzed by using 2-∆∆Ct method to get a relative expression 
levels (This protocol is modified from the shared folder from F100, DKFZ).  
 
2.2.12 Real-time RT-qPCR to quantify EBV transcripts 
RNA extracted with Trizol from LCLs was reverse transcribed with AMV-reverse 
transcriptase (Roche) using a mix of random primers. The primers and probes used to 
detect EBER, BZLF1, EBNA2, LMP1, LMP2A, and LMP2B are listed in the table. 
The PCR and data analysis was carried out using the universal thermal cycling 
protocol on an ABI STEP ONE PLUS Sequence Detection System (Applied 
Biosystems). All samples were run in duplicates, together with primers specific to the 
human GAPDH gene to normalize for variations in cDNA recovery (This protocol is 
modified from the shared folder from F100, DKFZ). 
 
2.2.13 Determination of EBER half-time 
We treated LCLs transformed by M81 or B95-8 wild type by adding RNA 
polymerase III inhibitor ML-60218 (100 µM, Sigma Aldrich) to the culture medium. 
Cells were collected at different treatment time and submitted to RT-qPCR (Wu et al., 
2003). 
 
2.2.14 Complementation experiments  
B1460 is a plasmid that contains a bi-directional tetracycline-inducible CMV 
promoter that encodes a truncated nerve growth factor receptor (NGFR) on one site, 
and the EBER1 and EBER2 in 4 copies on the other. B1249 contains only NGFR and 
was used as a negative control. M81/ΔEBER1+2 LCLs were transfected with either 
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B1249 or B1460 (contains M81 EBER1 and EBER2 in 4 copies) or B1510 (contains 
B95-8 EBER1 and EBER2 in 4 copies) and cultured with 1 µg/ml doxycycline for 21 
days. NGFR-positive cells were isolated with specific antibodies and used for protein 
and RNA analyses.  
 
2.2.15 Western blots  
Proteins were extracted with a standard RIPA buffer (150 mM NaCl, 0.5% NP-
40, 1% Sodium deoxycholat, 0.1% SDS, 5 mM EDTA, 20 mM Tris-HCl 
pH7.5, proteinase inhibitor cocktail (Roche)) for 15 min on ice followed by 
sonication to shear the genomic DNA. Up to 20 µg of proteins denatured in 
loading buffer for 10 min at 95 degree were separated on SDS-polyacryl-amide gels 
and electroblotted onto a nitrocellulose membrane (Hybond C, Amersham). After pre-
incubation of the blot in 3% milk dry powder in PBST (PBS with 0.1% Tween-20), 
the antibody against the target protein was added and incubated at 4 degree overnight. 
After extensive washings in PBST, the blot was incubated for 1 hr with suitable 
secondary antibodies coupled to horseradish peroxidase (goat anti-mouse (Promega), 
goat anti-rabbit (Life technologies), or rabbit anti-goat (Santa Cruz) IgG). Bound 
antibodies were revealed using the ECL detection reagent (Pierce) (This protocol is 
modified from the shared folder from F100, DKFZ).  
 
2.2.16 Measurement of CXCL8 production 
Cell culture supernatants were collected and analyzed for CXCL8 production by using 
a Human IL-8 (CXCL8) ELISA development kit (Mabtech) according to the 
manufacturer’s protocol.  
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2.2.17 Human cytokine array 
We seeded LCLs transformed by M81 or M81/∆E1+2 at 30 dpi at a density of 3*105 
per milliliter in a 24-well-plate. Cell culture supernatants were collected after 3 days 
seeding and filtered through a 0.22 µm filter. The filtered supernatants were analyzed 
for cytokine production by using a Human Cytokine Array kit (R&D Systems) 
according to the manufacturer’s protocol.  
 
2.2.18 SYBR Green real-time PCR 
Total RNA isolated from LCLs were reverse transcribed with AMV-reverse 
transcriptase (Roche) using a mix of random hexamers. 200 ng total RNA was used 
for reverse transcription.  
An example is given below for a 20 µl reaction containing the following components: 
4 µl   5x RT buffer  
2 µl   2mM dNTPs  
2 µl   random hexamers 
4 µl   MgCl2 
0.8 µl   AMV reverse transcriptase 
1 µl  RNA inhibitor 
1.2 µl   water 
15 µl in total Mix 
5 µl of RNA sample was added to the master mix and incubated on ice for 5 minutes. 
The RT reaction was running following program:  
25 ˚C  10 min 
42 ˚C  60 min  
90˚C   5 min 
4˚C   hold 
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Store final cDNA at –20 ˚C until required. Add 80 ul water and use 5ul per RT-PCR 
reaction.  
An example is given below for a 20 µl reaction containing the following components: 
10 µL   2x Power SYBR green PCR Mix  
1 µL  Forward primer (target gene) 
1 µL  Reverse primer  (target gene) 
3 µL   water 
+5.0 µL  cDNA sample 
20 µL in total  
And remember to do Internal Reference PCR (eg. GAPDH) 
10 µL   2x Power SYBR green PCR Mix  
1 µL  forward primer GAPDH (10µM) 
1 µL  reverse primer  GAPDH (10µM) 
3 µL   water 
+5.0 µL  cDNA sample 
20 µL in total       
The qPCR was run with the following settings: 
50 °C for 2 min (initial denaturation) 
95 °C for 10 min (denaturation) 
40 cycles:  
95 °C for 15 s 
60 °C for 1 min 
The qPCR results were analyzed by using 2-∆∆Ct method to get a relative expression 
levels (This protocol is modified from the shared folder from F100, DKFZ).  
 
2.2.19 Apoptosis assay 
Apoptosis was induced in LCLs generated with different wild types and mutants at 
40-60 days after infection. Cells were treated with Etoposide (4µg/ml, Sigma), 
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Staurosporine (4µg/ml, Sigma) or a DMSO solvent control for 20 hrs. Cells were also 
treated with Ionomycin (4µg/ml, Sigma Aldrich) for 48 hrs or Simvastatin (2µM, 
Calbiochem) for 5 days.  
Cells were then washed twice with ice-cold PBS, dried on glass slides and fixed with 
4% paraformaldehyde in PBS to perform a TUNEL assay that labels apoptotic cells 
with DNA breaks (Cell Death Detection Kit, TMR red, Roche) following the 
instruction of manufacturer. Cells were also stained with a rabbit antibody specific for 
cleaved caspase 3 (Cell signal technology).  
 
2.2.20 Exosomes isolation 
Exosomes were isolated from multiple EBV positive LCLs transformed with M81, 
M81∆E1+2, M81∆ZR, M81∆E1+2∆ZR, B95-8 viruses and RPMI1640 supplemented 
with 10% Exosomes Free FBS used as a negative control by differential ultra-
centrifugation as previously described. Briefly, 2x107cells in late log phase were used 
for exosomes extraction. Cell viability was checked by trypan blue and cultures with 
viabilities above 95% were used. For each cell line, culture supernatant was 
centrifuged at 1,000xg at 4 °C for 20 minutes to pellet down cells. The supernatant 
was carefully removed, and centrifuged at 2,000xg at 4 °C for 20 min to pellet down 
apoptotic bodies (ABs). The supernatant was then carefully removed, and centrifuged 
at 10,000xg at 4 °C for 30 min using SW32 Ti rotor (Beckman, Fullerton, USA) to 
pellet down microvesicles (MVs) and EBV particles. To further remove microvesicles 
and EBV particles, 0,22 µm filter was used. The supernatant was collected and 
centrifuged at 100,000xg at 4 °C for 70 minutes. The supernatant was carefully 
aspirated off and the exosome containing pellets were resuspended in PBS or RIPA 
buffer for further experiments (Ahmed et al., 2014).  
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2.2.21 Infection experiments in NSG mice 
We isolated human CD19+ B cells from buffy coats and exposed them to virus 
supernatants for 2 hours at room temperature under constant agitation at a MOI 
sufficient to generate 20% of EBNA2-positive cells. The infected cells were collected 
by centrifugation and washed twice with PBS. 2x105 infected primary B cells, 
equivalent to 4x104 EBNA2-positive cells, were injected intraperitoneally into NSG 
mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; NSG). The pre-established inclusion 
criteria in this study were healthy male NSG mice aged between 6 and 8 weeks. The 
mice were euthanized as soon as any clinical symptoms appeared (apathy, food 
refusal, ruffled hair, weight loss, palpable tumor). After careful autopsy, the organs 
were subjected to macroscopic and microscopic investigation, including hematoxylin 
and eosin (H&E) staining and immunohistochemistry (Tsai et al., 2017). 
 
2.2.22 Immunohistochemistry 
The organs from the studied mice were fixed in 10% formalin overnight and 
embedded in paraffin blocks. 3-µm-thin continuous sections were prepared and 
submitted to antigen retrieval at 98°C for 40 min in a 10 mM sodium citrate, 0.05% 
Tween 20 pH 6.0 solution. Bound antibodies were visualized with the Envision+ Dual 
link system-HRP (Dako). In parallel, adjacent sections were stained with H&E. The 
presence of EBV was detected by in situ hybridization with an EBER-specific PNA 
probe, in conjunction with a PNA detection kit (Dako) following the manufacturer’s 
protocol. Pictures were taken with a camera attached to a light microscope (Axioplan, 
Zeiss) (Tsai et al., 2017).  
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2.2.23 Statistical analysis 
All results obtained in in vitro studies with LCLs generated by EBV wild type or 
mutants with B cells from the same blood donor were paired and analyzed by paired 
student t-test. Unpaired student t-test was applied for analyzing the grouped NSG 
mice infected by either M81 or M81/ΔE1+2 virus. All p-values were analyzed as 2-
tailed and the values equal to 0.05 or less were considered significant unless 
indicated. The statistical analyses were performed with the GraphPad Prism 5 
software.  
 
2.2.24 Microarray analysis 
Three independent samples for each of the M81/∆E1+2 mutant and revertant were 
used for the RNA microarray analysis. RNA was isolated from each sample by 
using a TRIzol reagent and treated with DNase to remove genome DNA. RNA 
samples must be provided in a 1.5ml-tube and put on dry ice. The minimal 
concentration and volume for each sample is 50 ng/µl and 10 µl in total respectively. 
After preparing our RNA samples, we send them to Core Facility in DKFZ for further 
analysis. They preform experimental design, incoming QC for quality and 
concentration of all samples, labeling and hybridization to the microarrays, 
monitoring the quality at all steps, and basic data analysis. IIIumina HT12 platform 
was used to analyze our RNA samples.  
 
2.2.25 TLR7 experiments 
We used LCLs generated with M81∆E1+2 mutant for the agonist experiments. Cells 
were treated with Imiquimod (10 µg/ml, Santa Cruz), which is specific for TLR7 
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MyD88-dependent and NF-κB pathways or a DMSO solvent control for 36 hs. After 
36 hs post treatment, cell culture supernatants were collected and analyzed for 
CXCL8 production by using a Human IL-8 (CXCL8) ELISA development kit 
(Mabtech) according to the manufacturer’s protocol.  
We used LCLs generated with M81 wild type for the antagonist experiments. Cells 
were treated with synthetic oligonucleotides (4 µM), which is specific inhibitor for 
TLR7. After 3 days post treatment, cell culture supernatants were collected and 
analyzed for IL-8 production by using a Human IL-8 (CXCL8) ELISA development 
kit (Mabtech) according to the manufacturer’s protocol.  
Synthetic oligonucleotides with phosphorothioate backbones IRS 661 (5-TGC 
TTGCAAGCTTGCAAGCA-3) and a control oligonucleotide (5-
TCCTGCAGGTTAAGT-3) were synthesized by Eurofins (Dominguez-Villar et al., 
2015).  
 
2.2.26 EBER alignment  
 
We completed sequence alignments with 173 EBV EBER1 and EBER2 sequences 
published online. The identified polymorphisms were mostly located in the EBER2 
gene.   
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3 Results 
	
3.1 EBER expression varies after infection with different 
EBV strains 
 
3.1.1 EBER expression pattern in B cells infected with different EBV 
strains 
The EBERs have been implicated in transformation and lytic replication (Lee et al., 
2015; Swaminathan et al., 1991; Wu et al., 2007). Because these properties have been 
reported to be heterogeneous among different viral strains, we assessed EBER 
expression in the same B cells infected by different EBV strains by qPCR. We found 
that EBER2 was expressed 4 times more in cells infected with M81 than in the same 
cells infected with B95-8 (Fig. 3.1). Interestingly, the EBER2 expression levels 
mirrored the lytic replication levels previously recorded in these cells, with cells 
infected with M81 showing the highest levels of replication, followed by the viruses 
identified in gastric carcinomas SNU719, YCCEL1, GP202 and finally Akata and 
B95-8 (Tsai et al., 2017). There was some variation in EBER1 expression levels 
among cells infected by the different strains, but it was much milder than with 
EBER2.  
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Fig. 3.1 EBER expression levels in B cells infected with different EBV strains. 
We assessed EBER expression in B cells infected by different EBV strains by qPCR.  
The data are given relative to values obtained in LCLs generated with B95-8. The 
data represents the mean of three independent experiments ± SD.  
 
3.1.2 M81 EBER2 is more stable than its homolog in the B95-8 EBV 
genome 
The variable EBER2 expression levels could be potentially explained by a different 
half-life of the different EBERs. Therefore, we treated an LCL pair generated by M81 
or B95-8 infection with the drug (CAS 577784-91-9), an inhibitor of the RNA 
polymerase III and recorded EBER1 and EBER2 levels over time (Wu et al., 2003) 
(Fig. 3.2). This analysis showed marginal differences in the half-life of EBER1 
between the species. In contrast, EBER2’s half-life was 50% higher in cells infected 
with M81, relative to cells infected with B95-8. Thus, the higher EBER levels 
recorded in M81-infected cells can be at least in part ascribed to a longer half-life. 
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Fig. 3.2 Half-life of EBER1 and EBER2 from two different strains. We measured 
EBER expression in B cells infected by M81 and B95-8 strains by qPCR after 
treatment with a drug that specifically inhibits RNA polymerase III activity to 
determine the EBER half time. Result from one representative experiment is 
presented. 
 
3.1.3 EBV strains from NPC carry a unique EBER2 sequence 
To explain the differences between B95-8 and M81 EBER2, we completed this 
analysis by performing sequence alignments with all EBER sequences. We identified 
multiple polymorphisms that were mostly located in the EBER2 gene. These 
polymorphisms were not located in the sequences recognized by the primers and 
probes used for the analysis described in Fig. 3.1, except YCCEL1 that carries a 
polymorphism at position 26 (Table. 3.1).  
We found that the distribution of the different EBER2 polymorphisms in lymphoma, 
post-transplant lymphoproliferative disorder (PTLD), infectious mononucleosis (IM), 
and in EBV-associated gastric carcinoma (EBVaGC) was nearly identical. However, 
there are some polymorphisms that are seen more frequently in nasopharyngeal 
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carcinoma (NPC), as described in the introduction section, suggesting that NPCs carry 
a specific type of EBER2 that might have unique functions. Table. 3.1 displays the 
EBER2 polymorphisms in the multiple EBV strains analyzed in Fig. 3.1.  
The B95-8 EBER2 structure is reproduced from Lee et al (Fig. 3.3). The red positions 
display polymorphisms between B95-8 and M81 strains. In M81, position 44 is a G, 
position 46 is a U, position 57 is a G, position 61 is a U, position 93 is a C and 
position 168 is a G. 
 
Table. 3.1 EBER2 polymorphisms in multiple EBV strains 
 
The B95-8 strain was isolated from a patient with infectious mononucleosis (IM). 
Akata and P3HR1 were derived from Burkitt’s lymphoma cells. YCCEL1, SNU719, 
and GP202 were derived from gastric carcinomas cells. M81 was derived from a 
patient with nasopharyngeal carcinoma (NPC).  
 
EBV	strains	 26	 44	 46	 57	 61	 93	 168	
B95-8	 C	 T	 A	 A	 A	 A	 A	
Akata	 C	 T	 A	 A	 A	 A	 G	
YCCEL1	 A	 T	 A	 A	 A	 A	 G	
SUN719	 C	 T	 A	 A	 A	 A	 G	
GP202	 C	 T	 A	 A	 A	 A	 A	
P3HR1	 C	 T	 A	 A	 A	 A	 G	
M81	 C	 G	 T	 G	 T	 C	 G	
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Fig. 3.3 The B95-8 EBER2 structure. The B95-8 EBER2 structure is reproduced 
from Lee et al. The green region (+51 to +60) shows a typical Box B pol III promoter 
sequence in the B95-8 EBV genome (Howe and Shu, 1989). The red positions display 
polymorphisms between the B95-8 and M81 strains. In M81, position 44 is a G, 
position 46 is a U, position 57 is a G, position 61 is a U, position 93 is a C and 
position 168 is a G. 
 
3.1.4 EBER2 polymorphisms contribute to its expression  
To assess the impact of the 6 polymorphisms located in B95-8 and M81 EBER2, we 
introduced each of the mutations present in B95-8 EBER2 in the M81 EBER2 and 
reciprocally those mutations present in M81 EBER2 in the B95-8 EBER2. This 
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analysis showed that the ribonucleotides located at position 44, 46 and 61 had a strong 
influence on EBER2 expression, with M81-type mutations conferring higher 
expression levels than B95-8-type ones (Fig. 3.4). We conclude from this set of 
assays that strain-specific mutations influence the EBER2 expression levels. 
Alignments with available sequences showed that the sequence pattern displayed by 
the Akata EBER2 is the most common one and are shared with 68.6% of all EBV 
genomes. The B95-8 EBER2 is found in 7% of all 172 EBV genomes, and the M81 
EBER2 is common to 16.3% of all 172 EBV genomes, including the majority of 
strains isolated in NPCs.  
 
 
Fig. 3.4 EBER2 polymorphisms influence their expression levels. We assessed 
EBER expression in 293 cells transiently transfected with multiple EBER2 mutation 
plasmids by qPCR. pEGFP-C1 is an empty plasmid. B95-8.P.EBER2 means native 
B95-8 EBER2 in pEGFP-C1 plasmid. M81.P.EBER2 means native M81 EBER2 in 
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pEGFP-C1 plasmid. B95-8.P.EBER2.T44G means B95-8 native EBER2 that carries a 
mutation at position 44, T to G. M81.P.EBER2.G44T means M81 native EBER2 that 
carries a mutation at position 44, G to T. The data are given relative to values 
obtained in 293 cells transfected with B95-8.P.EBER2. The data represent the mean 
of three independent experiments ± SD. 
 
3.2 Lytically replicating cells contain more EBERs than 
latently infected B cells. 
 
3.2.1 Purification of BZLF1-positive cells in LCLs infected with wild 
type M81 
The apparent link between viral lytic replication and EBER2 expression levels led us 
to analyze the expression levels of this non-coding RNA in spontaneously replicating 
cells. To this end, we infected B cells with a recombinant M81 EBV that carries an 
inactive form of the rat CD2 gene driven by an early antigen promoter that is 
responsive to the BZLF1 protein that drives the onset of lytic replication. Thus, 
infected B cells undergoing lytic replication express CD2 at their cell surface and can 
be immunocaptured by a specific antibody (Lin et al., 2015). We quantified BZLF1 
expression in the CD2-positive and CD2-negative populations using quantitative RT-
PCR and western blot (Fig. 3.5). As expected, we found that only CD2-positive cells 
produced BZLF1 at the mRNA and protein levels. This implies that cells that express 
the BZLF1 mRNA also express the BZLF1 protein. This also suggests that these 
mRNAs are not subjected to massive miRNA interference.  
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Fig. 3.5 Purification of CD2-positive cells and CD2-negative cells. CD2-positive 
cells were isolated from LCLs generated with a M81 mutant that expresses a 
truncated form of rat CD2 behind an EA-D-responsive promoter. The CD2-positive 
cells were purified with a specific antibody. CD2-positive or CD2-negative cell 
populations were submitted to RT-qPCR to assess BZLF1 mRNA expression (top 
graph) and to a western blot analysis with a BZLF1-specific antibody (bottom 
picture). 
 
3.2.2 Lytically replicating cells express more EBERs than non-
replicating B cells 
We assessed EBER expression levels in the CD2-positive and CD2-negative 
populations by qPCR. We found that EBER1 and EBER2 are, on average, expressed 
5 and 10 times fold higher in lytically replicating B cells than in non-replicating ones, 
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respectively (Fig. 3.6). Thus, there is a positive relationship between EBV EBER 
RNAs and BZLF1 expression.  Replicating B cells expressed 40 times more EBER2 
than B cells latently infected with B95-8.  
 
Fig. 3.6 EBER expression pattern in CD2-positive cells and CD2-negative cells. 
The scatter plot shows the expression of viral EBER1 and EBER2 extracted from 
CD2-positive or CD2-negative cell populations obtained from 5 different LCLs 
generated with the CD2-expressing virus. A result from one LCL is indicated by a 
square. All the p values were obtained from paired student t tests.  
 
3.2.3 Lytic replication enhances EBER production 
Although replicating cells represent only a minority among infected cells, the very 
high EBER expression levels found in these cells are likely to influence total EBER 
levels. Therefore, we assessed the expression of these non-coding RNAs in LCLs 
generated with wild type M81 or its replication-defective M81/∆ZR version that lacks 
the BZLF1 and BRLF1 transactivators. While EBER1 was produced approximately at 
the same level in both types of LCLs, cells infected with M81 produced nearly twice 
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as much EBER2, relative to cells infected with the M81/∆ZR mutant (Fig. 3.7). 
Considering that only 5% of the cells undergo lytic replication, this suggests that 
replicating cells generate considerable amounts of EBER2 and to a lesser extent of 
EBER1. To confirm that lytic replication enhances EBER production, we transfected 
BZLF1 into LCLs generated with M81/∆Z. Forced expression of BZLF1 led to an 
increase in EBER1 and EBER2 expression that was comparable in intensity to the 
changes observed in spontaneously replicating cells (Fig. 3.7). Thus, EBERs, and in 
particular EBER2, are amplified in replicating cells. These data also suggest that the 
expression of EBER1 and 2 is independent from one another, with EBER2 being 
preferentially transcribed in replicating cells.  
 
(A)                (B) 
  
Fig. 3.7 EBERs are amplified in replicating cells. (A) We determined the EBER 
expression by qPCR in 4 different LCLs generated with M81/∆ZR virus. This scatter 
plot shows the ratio of EBER expression between M81/∆ZR-infected LCLs verse 
M81 wild type-infected LCLs. A result from one LCL is indicated by a square. Paired 
t-student tests were performed to analyze the data. (B) A LCL transformed by 
M81/ΔZ was stably transfected with a plasmid that encodes a truncated form of 
NGFR and BZLF1 or with a plasmid that encodes NGFR only (empty). The NGFR-
	 79	
positive cells were purified with a specific antibody. We determined the EBER 
expression extracted from BZLF1-positive or BZLF1-negative cell populations 
obtained from 4 different LCLs generated with the M81/∆Z virus. A result from one 
LCL is indicated by a square. Paired t-student tests were performed to analyze the 
data.  
 
3.2.4 EBV latent genes mRNA expression profile in replicating cells 
relative to non-replicating cells 
We then extended our analysis to quantify the expression level of some viral mRNAs 
in these 2 cell populations using quantitative RT-PCR. We found that EBNA2 and 
LMP1 transcripts, but not LMP2A are expressed at higher levels in replicating cells 
than in non-replicating cells (Fig. 3.8).  
 
Fig. 3.8 EBV viral mRNA expression profile in replicating cells and in non-
replicating cells. The scatter plot shows expression of viral EBNA2, LMP1, and 
LMP2A mRNAs extracted from CD2-positive or CD2-negative cell populations 
obtained from 5 different LCLs generated with the CD2-expressing virus. A result 
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from one LCL is indicated by a square. All the p values were obtained from paired 
student t tests.  
 
3.3 M81 EBER2 stimulates spontaneous lytic replication in 
B cells 
 
3.3.1 B cells infected with a M81 virus devoid of the EBER RNAs 
display decreased spontaneous lytic replication in B cells 
The EBERs have been implicated in the control of virus production, but different 
groups reported contradictory results (Lee et al., 2015; Swaminathan et al., 1991). To 
delineate the contribution of the EBERs to viral functions, we generated a set of 
triplets that included the wild type M81 virus, an EBER1 and 2 M81 double knockout 
and a revertant thereof (Fig. 3.9).  
We used these viruses to generate a panel of LCLs and assessed lytic replication in 
the infected cells. To this end, we monitored the expression of the BZLF1 protein in 
infected cells using western blot. The Epstein-Barr virus (EBV) immediate-early 
protein BZLF1 is a transcriptional activator that mediates the initiation of lytic 
replication (Mauser et al., 2002). This assay showed a 2 to 5 decrease in BZLF1 
expression at 35 days post infection (dpi) in B cells infected with the M81/∆E1+2 
virus, relative to wild type controls, in three investigated sample sets (Fig. 3.10). 
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Fig. 3.9 Construction of the M81 EBER non-coding RNAs mutants. (A) 
Schematic map of a segment from the rM81 genome that encompasses the EBER 
genes region. The deletion mutants were obtained by replacing the EBER1 and 
EBER2 with a kanamycin resistance cassette. (B) These restriction analyses from 
DNA Bacmid minipreparations show the restriction pattern of the M81/ΔE1, 
M81/ΔE2, M81/ΔE1+2 and M81/ΔE1+2 revertant mutants. The investigated samples 
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include rM81 bacmids after construction in E.coli or after rescue from the producer 
cell lines. The viral DNAs were cleaved with BamHI and separated on an agarose gel. 
The parental rM81 recombinant EBV plasmid was loaded as a control. The arrows 
indicate the viral DNA fragments whose sizes differ between the wild type rM81 and 
the mutants as illustrated in the schematic shown in (A).  
  
 
 
Fig. 3.10 The deletion of the EBER RNAs decreases lytic replication. We 
performed immunoblot analyses on LCLs transformed with M81, M81/∆E1+2 and 
M81/∆E1+2 Rev with antibodies specific for BZLF1 and actin. The graph of bars 
shows the relative intensity of the signals quantified by the ImageJ software. 
 
Sample 1 Sample 2 Sample 3 
36 kDa BZLF1 
actin  42 kDa 
M81 ∆E1+2 ∆E1+2 
  Rev 
M81 ∆E1+2 ∆E1+2 
  Rev 
M81 ∆E1+2 ∆E1+2 
  Rev 
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3.3.2 M81 EBER could affect the initiation of BZLF1 in EBV-
infected B cells 
We confirmed these results with immunofluorescence stains performed at three 
different time points after transformation using antibodies specific to BZLF1. At all 
investigated time points, the M81/∆E1+2 mutant displayed a lower percentage of 
replicating cells than wild type M81 virus (Fig. 3.11).  
 
 
Fig. 3.11 The deletion of the EBER RNAs decreases lytic replication. This picture 
shows the BZLF1 expression pattern in 8 different LCLs transformed by M81 or 
M81/ΔE1+2, as determined by BZLF1 immunofluorescence staining. The percentage 
of BZLF1-positive cells in LCLs from multiple B-cell donors at different days post 
infection (dpi) is given in the scatter plot. All the p values were obtained from paired t 
tests performed with the two types of LCLs.  
M81 M81/∆E1+2 
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3.3.3 Deletion of M81 EBER also affects viral late lytic production 
We further confirmed these results with immunofluorescence stains performed at 
three different time points after transformation using antibodies specific to gp350. 
Gp350 is expressed during the late phase of the lytic cycle and is a major component 
of the mature virion. At all investigated time points, the M81/∆E1+2 mutant displayed 
a lower percentage of replicating cells than wild type M81 virus (Fig. 3.12).  
 
 
Fig. 3.12 The deletion of the EBER RNAs decreases virus production. This 
picture shows the gp350 expression pattern in 8 different LCLs transformed by M81 
or M81/∆E1+2 as determined by gp350 immunofluorescence staining. The percentage 
of gp350-positive cells in LCLs from multiple B-cell donors at different days post 
infection (dpi) is given in the scatter plot. All the p values were obtained from paired t 
tests performed with the two types of LCLs.  
M81	 M81/∆E1+2	
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3.3.4 M81 EBER2 plays an important role in spontaneous lytic 
replication, but EBER1 is also involved in the control of this process. 
We then wished to determine which of the EBERs was responsible for the increased 
replication levels. To this end, we constructed M81 knock out viruses that lacked 
either EBER1 or EBER2 and repeated the aforementioned replication experiments. 
These results showed that the deletion of EBER2 but not of EBER1 reduces lytic 
replication. However, deletion of both EBERs has a stronger impact on lytic 
replication than deletion of EBER2 only, suggesting that both molecules contribute to 
this process, although EBER2 plays a much more important role than EBER1 (Fig. 
3.13).  
 
 
 
Fig. 3.13 M81 EBER2 plays a predominant role in lytic replication in B cells. We 
showed one immunoblot analysis performed on LCLs transformed with M81, 
M81/∆E1, M81/∆E2, and M81/∆E1+2 with antibodies specific for BZLF1 and actin. 
The scatter plot shows the relative intensity of the signals quantified by the ImageJ 
BZLF1 
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software from 6 independent samples. The data are given relative to values obtained 
in LCLs generated with M81. All the p values were obtained from paired t tests 
performed with the two types of LCLs.  
 
 
3.4 The EBER2 homolog on the B95-8 EBV genome does not 
influence spontaneous virus lytic replication in B cells 
 
3.4.1 Complementation of M81/∆E1+2 LCLs with M81 EBERs, but 
not with B95-8 EBERs increases spontaneous lytic replication 
Similar experiments were performed with the B95-8 derived virus but neither the cell 
samples infected with wild type virus nor those infected by the EBER1+2 null mutant 
showed evidence of lytic replication (Data not shown). Thus, the B95-8 EBERs are 
not responsible for the absence of virus production in B cells after infection with B95-
8. 
We continued the characterization of B95-8 EBERs by performing complementation 
experiments and by constructing hybrid EBV viruses in which the EBER genes are 
exchanged between the viruses. To this end, we introduced multiples copies of the 
EBERs from B95-8 or M81 cloned in tandem (Komano et al., 1999) under the control 
of a tetracycline-inducible promoter that also drives the expression of a truncated rat 
CD2 protein. After transfection, the CD2-positive cells were purified to obtain a 
homogeneous cell population that we found to express the different EBERs at 40 to 
60% of the levels seen in cells infected with wild type virus (Fig. 3.14). 
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Transfection of the M81 EBERs but not of the B95-8 EBERs restored BZLF1 
expression in B cells infected with the M81/∆E1+2 mutant (Fig. 3.14). As 
complementation of both M81 and B95-8 EBERs cloned under a tet-inducible 
promoter led to nearly similar expression levels, this suggested that polymorphisms 
between both types of EBER explain the differences between the viral isolates. 
 
                   
Fig. 3.14 M81 EBER2, but not B95-8 EBER2 influences lytic replication. A LCL 
transformed by M81/ΔE1+2 was stably transfected with a plasmid that encodes a 
truncated form of NGFR and both EBER1 and EBER2 from M81 or from B95-8 
strain or with a plasmid that encodes NGFR only (empty). The NGFR-positive cells 
were purified with a specific antibody. We determined the EBERs expression in these 
cells relative to M81 LCL (left panel) and their BZLF1 protein expression (right 
panel). These data represent three independent experiments.  
 
3.4.2 A M81 virus that carries B95-8’s EBERs displays reduced 
spontaneous lytic replication in B cells  
Analysis of the hybrid viruses yielded similar results. The M81 virus that carries B95-
8 EBERs expressed EBERs at levels comparable to those seen in cells infected with 
B95-8 and lower than in cells infected with M81 (Fig. 3.15). This exchange virus 
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produced BZLF1 at levels similar to those observed in cells infected with 
M81/∆E1+2, confirming that the M81 EBER have specific properties (Fig. 3.15). 
Introduction of the M81 EBERs into the B95-8 genome did not lead to lytic 
replication, suggesting that the EBERs only amplify spontaneous lytic replication but 
do not initiate it, a finding in line with the observation that cells infected with 
M81/∆E1+2 still show some degree of lytic replication.  
								 						 		
Fig. 3.15 A M81 virus that carries B95-8’s EBERs displays reduced lytic 
replication in B cells. We determined EBERs expression levels in these LCLs 
relative to M81 LCL by qPCR. The data represents the mean of three independent 
experiments ± SD. We showed one immunoblot analysis performed on LCLs 
transformed with M81, ∆E1+2, ∆E1+2 Rev, and Exchange viruses (M81_B95-
8.E1+2) with antibodies specific for BZLF1 and actin. The scatter plot shows the 
relative intensity of the signals quantified by the ImageJ software from 4 independent 
samples. A result from one LCL is indicated by a square. The data are given relative 
to valuse obtained in LCLs generated with M81. All the p values were obtained from 
paired t tests performed with the two types of LCLs.  
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3.5 M81 EBERs control lytic replication in vivo 
 
We wished to confirm our data using an in vivo model of EBV infection and injected 
resting B cells exposed to M81/∆E1+2 or M81/∆E1+2 Rev into immuno-suppressed 
NSG mice. We terminated the experiment at 6 weeks post injection. We analyzed the 
tumor tissues for EBER, BZLF1, gp350, and EBNA2 expression. EBNA2 is a latent 
EBV protein expressed in proliferating cells. Continuous tissue sections were stained 
with hematoxylin and eosin (H&E), immunostained with antibodies specific for 
BZLF1, gp350, EBNA2, or subjected to an in situ hybridization with an EBER-
specific probe. As expected, the mice infected with the M81/∆E1+2 virus did not 
express the EBER molecules and showed reduction in the expression of the early 
marker (BZLF1) and late marker (gp350) of lytic replication as shown in Fig. 3.16A. 
However, the percentage of infected cells that expressed EBNA2 among the EBV-
infected population showed no difference between wild type- and ΔE1+2-infected 
mice (Fig. 3.16B). Therefore, we used EBNA2 expression to normalize the 
percentage of BZLF1 positive cells between wild type- and ∆E1+2-infected mice. All 
infected tissues contained cells expressing the early marker of lytic replication 
(BZLF1), but the ratio between BZLF1 and EBNA2 proved to be globally lower in 
the mice infected with the virus devoid of the EBER RNAs (Fig. 3.16D). We 
conclude that M81 EBERs control lytic replication in vivo.  
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Fig. 3.16 M81 EBERs control lytic replication in vivo. (A) These pictures show 
immunohistochemistry in the tumors that developed in the gut. Continuous tissue 
sections were stained with hematoxylin and eosin (H&E), immunostained with 
antibodies specific for BZLF1, gp350, EBNA2, or subjected to an in situ 
hybridization with an EBER-specific probe. Among 5 M81/∆E1+2 infected mice, 
they all exhibited a lower percentage of BZLF1-positive cells. (B-C) The number of 
total cells per 0.04µm2 (surface of the field at high magnification) is given. The 
boxplots display the ratio between (B) EBNA2- or (C) BZLF1-positive cells versus 
total cells. (D) This boxplot display the ratio between BZLF1-positive cells versus 
EBNA2-positive cells. A result from one mouse is indicated by a square. We used 
two-tailed unpaired student t test for all the results.  
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3.6 Latent membrane proteins (LMPs) expression profile in 
B cells infected with EBER knockout in M81 and B95-8 
strain 
 
3.6.1 mRNAs expression profile in B cells infected with EBER 
knockout in M81 and B95-8 strain 
EBER2 was recently shown to bind PAX5 and to promote PAX5 binding to the 
terminal repeat region of the EBV genome (Lee et al., 2015). Knockdown of EBER2 
by small interfering RNA (siRNA) caused a 50% increase in LMP1 and LMP2 RNA 
levels in this study (Lee et al., 2015). Using quantitative TaqMan PCR (qPCR), we 
did not observe any significant difference between the M81 EBER deletion LCLs and 
wild-type EBV LCLs in the levels of LMP2A and LMP2B RNA (Fig. 3.17B and C), 
but LMP1 RNA levels were slightly lower at early days post infection (30-50dpi) 
when M81 EBER2 was deleted (Fig. 3.17A). The same experiments were performed 
in the B95-8 EBV strain. Using quantitative TaqMan PCR (qPCR), we also did not 
observe any significant difference between the B95-8 EBER deletion LCLs and wild-
type EBV LCLs in the levels of LMP2A and LMP2B RNA (Fig. 3.17B and C), but 
LMP1 RNA levels were 2-fold higher at early time day post infection (30-50dpi) 
when B95-8 EBERs were deleted (Fig. 3.17A).  
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(A)                                         (B)                                       (C) 
 
Fig. 3.17 mRNAs expression profile in B cels infected with the EBER deletion 
mutants in M81 and B95-8 strains. (A) We determined the LMP1 expression by 
qPCR in LCLs generated with multiple EBER mutants at different days post infection 
(dpi) in M81 and B95-8 EBV strains. (B) We determined the LMP2A expression by 
qPCR in LCLs generated with multiple EBER mutants at different days post infection 
(dpi) in M81 and B95-8 EBV strains. (C) We determined the LMP2B expression by 
qPCR in LCLs generated with multiple EBER mutants at different days post infection 
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(dpi) in M81 and B95-8 EBV strains. The data are given relative to values obtained in 
LCLs generated with M81 or B95-8. A result from one LCL is indicated by a square. 
All the p values were obtained from paired t tests performed with the two types of 
LCLs.  
 
3.6.2 protein expression profile in B cells infected with EBER 
knockout in M81 and B95-8 strain 
The LMP1 and LMP2A protein levels were comparable in EBER KO and WT 
generated LCLs on the basis of both M81 and B95-8 EBV strains (Fig. 3.18), and 
there was no apparent correlation with EBER expression. Our results thus provide 
some support for the earlier proposed model that B95-8 EBER2 reduces the level of 
LMP1 RNA, but find instead that M81 EBER2 increases the level of LMP1 RNA. 
These discrepancies could be explained by different properties of different EBV 
strains and that could probably result from polymorphic EBER2 sequences.  
 
 
Fig. 3.18 Proteins expression profile in B cells infected with EBER mutant in 
M81 and B95-8 strains. We performed immunoblot analyses on LCLs transformed 
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with M81 or B95-8 wild type strains, and corresponding EBER mutants with 
antibodies specific for LMP1, LMP2A, and actin. Top pictures show immunoblots in 
M81 strain and below pictures show immunoblots in B95-8 strain.  
 
3.7 M81 EBER modulates lytic replication by inducing 
CXCL8 
3.7.1 RNA microarray analysis 
The data gathered so far led us to conclude that M81 EBERs play an important role in 
stimulating spontaneous virus lytic replication in B cells. We wished to understand 
the mechanistic link between EBER expression and lytic replication in B cells. To this 
end, we generated three panels of LCLs infected with M81 wild type and M81/∆E1+2 
mutant and subjected them to a RNA microarray analysis. Table 3.2 shows the top 10 
up-regulated and down-regulated genes following EBER expression. We found that 
CXCL8 mRNA was significantly down regulated in B cells infected with the 
M81/∆E1+2 virus.  
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Table 3.2 Top 10 genes in up-regulation and down-regulation 
 
Previous studies have also demonstrated that EBERs can induce the transcription of 
various cytokines, such as interleukin-10 (IL-10) in BL cells, insulin-like growth 
factor-1 (IGF1) in epithelial cells and IL-9 in T cells (Iwakiri et al., 2005; Samanta et 
al., 2008; Yang et al., 2004). Thus, we also subjected two pairs of LCLs to a Human 
Cytokine Array screening. We found that CXCL8 protein expression level was 
slightly lower in B cells infected with the M81/∆E1+2 virus than in B cells infected 
Symbol Fold Change (∆E1+2/Rev) 
FXYD2 12,67 
HLA-DRB5 3,51 
UGT2B17 3,22 
ATP1B1 3,19 
DBNDD2 3,02 
UGT2B7 2,82 
BHLHE22 2,80 
LINCR 2,72 
LAD1 2,58 
C1orf106 2,56 
LOC401845 0,18 
CXCL8 0,35 
COL5A1 0,41 
LOC649923 0,41 
LOC100134331 0,42 
LOC647450 0,45 
SGK 0,46 
ADM 0,46 
LOC652694 0,45 
RN7SK 0,49 
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with the M81 WT. However, we could not identify any difference in IL-10 expression 
between M81/∆E1+2 and M81 WT LCLs (Fig. 3.19). 
 
Fig. 3.19 Human Cytokine Array screening. We seeded LCLs transformed by M81 
WT or M81/∆E1+2 at 30 dpi at a density of 3*105 per milliliter in a 24-well-plate. 
Cell culture supernatants were collected after 3 days seeding and filtered through a 
0.22 µm filter. The filtered supernatants were analyzed for cytokine production by 
    Cytokines expression levels in M81 LCLs  
Coordinate Target/Control Signal intensity 
A7,A8 MIP-1α/MIP-1β Very high 
E3,E4 MIF High 
A9,A10 CCL5/RANTES High 
B5,B6 CXCL12/SDF-1 Medium 
B11,B12 ICAM-1/CD54 Medium 
D5,D6 IL-16 Medium 
C11,C12 IL-6 Low 
C13,C14 CXCL8 Low 
C15,C16 IL-10 Low 
High 
Low 
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Note: A1,A2, A19,A20, E1,E2 are positive controls; E19,E20 is a negative control. The 
positive control spots are standardized amounts of biotinylated IgG. They are used for signal 
normalization, monitoring of the detection step, and to help orient the array image. The 
negative control spots are printed with buffer only, and thus are not expected to give signals. 
Negative control spots are used for background subtraction. 
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using a Human Cytokine Array kit (R&D Systems) according to the manufacturer’s 
protocol. 
 
3.7.2 CXCL8 expression in LCLs infected with multiple viruses 
We concentrated on CXCL8 and confirmed its regulation by EBERs using qPCR and 
ELISA in LCLs generated with multiple viruses. These assays showed that CXCL8 is 
clearly down regulated at both the mRNA and the protein levels in M81/∆E1+2 
infected B cells, relative to wild type controls, including M81 WT and M81/∆E1+2 
Rev (Fig. 3.20). 
 
  (A)                (B) 
       
Fig. 3.20 CXCL8 expression in B cells infected with multiple viruses. (A) We 
determined CXCL8 mRNA expression in the same B cells infected by multiple EBV 
viruses by qPCR. The data are given relative to values in LCLs generated with M81. 
The data represents the mean of three independent infection experiments ± SD. (B) 
We assessed CXCL8 expression in the different 4 LCLs generated with multiple EBV 
viruses by ELISA. We used two-tailed paired student t test for all the results.  
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3.7.3 CXCL8 can compensate the absence of EBER RNA in the role 
of lytic replication 
In order to understand why CXCL8 down-regulation in LCLs infected with the 
M81/∆E1+2 virus results in decreased lytic replication in B cells, we performed 
complementation assays by continuously adding recombinant CXCL8 to LCLs 
infected with the M81/∆E1+2 virus for 7 days. We quantified BZLF1 expression in 
LCLs with or without CXCL8 supplementation, relative to wild type controls. We 
found that BZLF1 expression is increased in M81/∆E1+2 LCLs with CXCL8, relative 
to LCLs without CXCL8 (Fig. 3.21). Importantly, CXCL8 supplementation can 
completely compensate the absence of EBER RNA in the role of virus lytic 
replication, suggesting that CXCL8 represents the main target of this EBER molecule. 
We conclude that M81 EBERs stimulate the expression of CXCL8, and that this 
cytokine increases lytic replication in infected B cells.  
 
 
Fig. 3.21 CXCL8 can compensate the absence of EBER RNA in the role of lytic 
replication.  We assessed BZLF1 expression by a BZLF1-specific antibody by 
western blot in the CXCL8 complementation assay (top picture) and bottom graph 
BZLF1 
actin 
 ∆E1+2   +CXCL8   M81wt      
Sample 1 
36 kDa 
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shows 4 independent experiments. A result fron one LCL is indicated by a square. We 
used two-tailed paired student t test for all the results.  
 
3.7.4 The EBER2 homolog on the B95-8 EBV genome cannot induce 
CXCL8 production 
After performing the aforementioned experiments, we concluded that M81 EBER2 
stimulates spontaneous virus lytic replication in B cells. However, its homolog in the 
B95-8 genome loses this property in the control of spontaneous virus lytic replication. 
We also concluded that M81 EBER2 could induce CXCL8 production and that 
CXCL8 was able to compensate the absence of M81 EBER2 in the role of virus lytic 
replication. Next, we wished to understand the role of B95-8 EBER2 in the 
stimulation of CXCL8 production in B cells. We infected B cells with the M81 virus 
that carries B95-8’s EBER2 and performed qPCR and ELISA analysis in these LCLs. 
We found that the expression of CXCL8 in B cells infected with the M81 hybrid virus 
is lower than the expression in wild type controls, including M81 WT and M81/∆ZR 
(Fig. 3.20).  In addition, we performed EBER complementation assays. We 
transfected M81/∆E1+2 infected LCLs with a plasmid that encodes multiple copies of 
the M81 EBERs or B95-8 cloned in tandem under the control of a tetracycline-
inducible promoter that also drives the expression of a truncated nerve growth factor 
receptor (NGFR) or with a control vector. After transfection, the NGFR-positive cells 
were purified to obtain a homogeneous cell population that expresses EBERs at 
approximately 50% of the levels seen in cells infected with wild type virus (Fig. 
3.22). We quantified CXCL8 expression in these cell populations and found that only 
M81 EBER could increase CXCL8 expression, however, B95-8 EBER could not (Fig. 
3.22).  
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           (A)                   (B) 
       
Fig. 3.22 M81 but not B95-8 EBER2 can induce CXCL8 production. A LCL 
transformed by M81/ΔE1+2 was stably transfected with a plasmid that encodes a 
truncated form of NGFR and both EBER1 and EBER2 from M81 or from B95-8 
strain or with a plasmid that encodes NGFR only (empty). The NGFR-positive cells 
were purified with a specific antibody. We determined the EBERs expression by 
qPCR in these cells relative to M81 LCL (left panel) and their CXCL8 protein 
production by ELISA (right panel). This data represents three independent 
experiments.  
In this chapter, we conclude that M81 EBER2 enhances CXCL8 and BZLF1 
production, but its homolog in the B95-8 genome is compromised in these processes.  
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3.8 Exosomal fractions of B cells infected with wild type M81 
that carries the EBER molecules are able to increase 
CXCL8 and BZLF1 production 
 
3.8.1 EBER is able to increase CXCL8 and BZLF1 production after 
exposure to exosomes from infected cells 
The data accumulated so far led us to conclude that M81 but not B95-8 EBER2 
enhances CXCL8 production and spontaneous virus lytic replication.  
CXCL8 is a chemokine that is secreted as a result of an activation of the immune 
system, including its innate branch. We searched for mechanisms that could link 
EBER and CXCL8 production. Because lytic replication takes place in infected B 
cells in the absence of T cells or other members of the adaptive immune response, we 
deemed it more likely that CXCL8 was activated in M81-infected B cells by the 
innate immune response. However, EBER is mainly located in the nucleus of infected 
cells and cannot a priori access restriction factors that are mainly located in the 
cytoplasm or in the endosome compartments. EBER has been reported to be 
incorporated in exosomes produced by infected cells (Ahmed et al., 2014). These 
subcellular organelles could access dendritic cells and activate TLR3 in the endosome 
(Iwakiri et al., 2009). We tested whether such a mechanism could also act in a 
paracrine manner. However, TLR3 is not expressed in B cells (Hanten et al., 2008). 
We canvassed a transcriptome of EBV-infected B cells and looked at the expression 
of TLR members expressed in the endosome. This analysis confirmed that while 
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TLR3 and TLR8 are hardly expressed in infected B cells, TLR7 is expressed in these 
cells, as previously reported (Hanten et al., 2008).  
We performed immunoblot analyses on exosomal fractions isolated from multiple 
LCLs supernatants with antibodies specific for CD63, an exosome marker (Wang et 
al., 2017). We found that the isolates indeed contained CD63 proteins and thus 
confirmed that the isolates contain exosomes (Fig. 3.23A). We also performed 
immunoblot analyses on exosomal fractions with antibodies specific for LMP1, and 
we found that LMP1 proteins can be detected in the exosomal fractions, as previously 
reported (Flanagan et al., 2003) (Fig. 3.23A). We measured EBER2 expression by 
qPCR in the exosomal preparations isolated form the same cell numbers and we found 
that EBER2 expression is 4 times lower in exosomes generated from cells infected 
with B95-8 compared to the cells infected with M81 (Fig. 3.23B). These results 
suggested that we successfully isolated exosomal fractions of B cells and these 
exosomes carry the EBER molecules. To learn whether EBER increases CXCL8 and 
BZLF1 production via exosomes, we assessed CXCL8 expression by ELISA in 
M81/∆E1+2 LCLs treated with exosomes isolated from multiple LCLs. We found that 
exosomal fractions of B cells infected with wild type M81 or M81/∆ZR that carry the 
EBER molecules are able to increase CXCL8 and BZLF1 production. However, 
exosomal fractions of B cells infected with M81/∆E1+2 or M81/∆E1+2/∆ZR that do 
not carry the EBER molecules are unable to do it.  
Exosomes from cells infected with B95-8 contained much less EBER than cells 
infected with M81 (Fig. 3.23B). However, the inability of B95-8 EBER2 to potentiate 
lytic replication could not be ascribed to a low production of EBER2, as incubation of 
a null EBER1+2 M81 LCL with large amounts of B95-8 exosomes had no influence 
on replication. On the other hand, exposure of cells with M81 exosomes at the level 
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found in B95-8 exosomes led to a weak potentiation of BZLF1 production. Thus, the 
inability of B95-8 exosomes to stimulate lytic replication can be ascribed to EBER2 
polymorphisms. 
We conclude that the M81 EBER molecules located in exosomes enhance CXCL8 
and BZLF1 production.  
(A)                                                                   (C) 
                
(B)          (D)                                                                                       
                               
         
Fig. 3.23  M81 EBER molecules located in exosomes enhance CXCL8 and 
BZLF1 production. (A) We performed immunoblot analyses on exosomal fractions 
isolated from R10 (medium only), M81/∆E1+2, M81 WT, B95-8 WT, 
M81/∆E1+2/∆ZR and M81/∆ZR LCLs supernatants with antibodies specific for 
CD63, LMP1, and actin. (B) We assessed EBER2 expression by qPCR in the 
exosomal fractions of B cells infected with M81, M81/∆ZR, and B95-8. The data are 
given relative to values obtained in LCLs generated with M81. Data is the mean of 
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three independent experiments ± SD. (C) We assessed CXCL8 expression by ELISA 
in M81/∆E1+2 LCLs after treatment with exosomes isolated from multiple LCLs. (D) 
We performed immunoblot analyses on these exosomes-treated-LCLs with antibodies 
specific for BZLF1 and actin. Fig. C and Fig. D represent three independent 
experiments. 
 
3.8.2 The EBER molecules can be visualized after exosome uptake by 
B cells 
The data gathered suggested that exosomes transferred the EBERs into the cells 
transformed by M81/∆E1+2. Exosomes are thought to be incorporated into their 
target cells via endocytosis (Mulcahy et al., 2014). Therefore, we exposed 
M81/∆E1+2 LCLs to exosomes from wild type M81 under conditions that inhibited 
(incubation at + 4°C), or stimulated endocytosis (incubation at + 37°C, inclusion of 
polybrene combined to centrifugation) and performed an in situ hybridization on the 
treated LCLs with an EBER-specific probe. This assay unequivocally revealed that 
EBER are incorporated into cells from exosomes and that the incorporation of EBER 
into cells increased in parallel with the conditions that enhance endocytosis (Fig. 
3.24). After cytocentrifugation in the presence of polybrene at 37°C at one hour, 40% 
of the treated cells had incorporated EBER to a level very close to wild type levels. 
Why some LCL cells are resistant to this type of endocytosis remains to be 
determined. This treatment also restored wild type levels of replication (Fig. 3.24). 
We also incubated a ∆EBER1+2 LCL with exosomes from wild type M81 LCLs 
without enhancers of endocytosis ether at 37°C or at 4°C. Only cells incubated at 
37°C with the exosomes showed accumulation of EBER molecules, albeit at much 
	 105	
lower levels that in the presence of endocytosis enhancers. Cells incubated at 4°C 
with the exosomes did not show any evidence of endocytosis. 
(A) 
 
(B) 
 
(C)  
 
Fig. 3.24  The EBER molecules can be visulized after exosome uptake by B cells. 
(A) We performed EBER staining in M81/∆E1+2 LCLs treated with exosomal 
fractions isolated from M81 WT LCLs supernatants in the presence of polybrene (6 
µg/ml) and spinoculation at 300 g for 1 h at 24°C. The cells were returned to the 
incubator for 3 h at 37°C. These pictures show an example of EBER staining. (B) We 
assessed CXCL8 expression by ELISA in M81/∆E1+2 LCLs after treatment with 
exosomes isolated from LCLs for 2 days and we performed immunoblot analyses on 
these exosomes-treated-LCLs with antibodies specific for BZLF1 and actin. Fig. B 
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represents three independent experiments. (C) This picture shows an example of 
BZLF1 immunofluorescence staining in M81/∆E1+2 LCLs after treatment with 
exosomes.  
3.8.3 Exosomes uptake is dose-dependent in B cells 
We then repeated the experiments with increasing amounts of exosomes and observed 
a clear dose-dependent relationship, although the maximum enhancement of lytic 
replication was reached at exosome concentrations lower than those observed in cells 
infected with wild type virus. We then compared EBER production in infected cells 
and in exosomes. Interestingly, there was a clear parallel between the level of EBER 
production in these two types of structures (Fig. 3.25A). Also there was a positive 
relationship between the quantity of exsomes applied to M81/∆E1+2 LCLs and the 
CXCL8 production levels (Fig. 3.25B).  
(A)                                                               (B) 
       
 
Fig. 3.25  Exosomes uptake is dose-dependent in B cells. (A) We assessed EBER 
expression in M81/∆E1+2 LCLs treated with different dose of exosomal fractions 
isolated from M81 WT LCLs. (B) We assessed CXCL8 expression by ELISA in 
exosome treated LCLs. This represents three independent experiments.  
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3.9 The impact of EBER2 on EBV lytic replication required 
a functional TLR7, a sensor of viral single-stranded RNA 
(ssRNA) 
 
3.9.1 Transcriptome data in EBV-infected B cells 
We concluded that exosomal fractions of B cells infected with wild type M81 that 
carries the EBER molecules are able to increase CXCL8 and BZLF1 production. The 
molecular mechanism by which M81 EBER2 induces CXCL8 expression needed to 
be clarified. Toll-like receptors (TLRs) are a class of proteins that play a key role in 
the innate immune system. TLR3, TLR7, and TLR8 can sense double-stranded RNA 
or single-stranded RNAs. According to our transcriptome data generated in M81 WT 
and B95-8 WT transformed LCLs, TLR7, a sensor of single-stranded RNA, is highly 
expressed after EBV infection. However, TLR3 and TLR8 are hardly expressed in 
these two types of EBV-transformed LCLs (Table 3.3), although TLR3 is expressed 
in T and NK cells. It is known that TLR7 is located in the endosome (Heil et al., 2003; 
Lee et al., 2003; Nishiya and DeFranco, 2004). Those observations indicate that in 
principle EBER might be able to activate signaling through TLR7 via exosomes and 
induce the production of cytokine CXCL8.  
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Table 3.3 Transcriptome data in M81 and B95-8 LCLs 
 
 
3.9.2 CXCL8 production is increased after TLR7 agonist treatment 
In an attempt to demonstrate that TLR7 is involved in the induction of CXCL8, we 
treated LCLs transformed by M81/∆E1+2 at 30-40 dpi by adding the TLR7 agonist 
Imiquimod to the culture medium for 36 hrs. We included DMSO-treated cells as 
controls. Cell culture supernatants were collected and analyzed for CXCL8 
production by ELISA. Cells were then washed twice with ice-cold PBS and submitted 
to protein analysis. We found that Imiquimod treatment can enhance CXCL8 
production and BZLF1 expression in M81/∆E1+2 LCLs (Fig. 3.26).  
 
                                                    
 
Fig. 3.26 CXCL8 production is increased after treatment with the TLR7 agonist. 
We assessed CXCL8 production by ELISA on LCLs transformed by M81/∆E1+2 
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after treating with the TLR7 agonist Imiquimod (5µg/ml) (left graph). The data shows 
the mean of three independent experiments ± SD. We performed immunoblot 
analyses on the LCLs with antibodies specific for BZLF1 and actin (middle picture). 
The middle picture shows one sample and the right graph represents three 
independent experiments.  
 
3.9.3 CXCL8 production is decreased after TRL7 antagonist 
treatment 
We then treated LCLs transformed by M81 WT by adding the TLR7 antagonist IRS 
661 to the culture medium for 72 hrs. IRS 661 consists of synthetic oligonucleotides 
with phosphorothioate backbones and it specifically targets TLR7 (Dominguez-Villar 
et al., 2015). We included Control-Oligos-treated cells as controls. Cell culture 
supernatants were collected and analyzed for CXCL8 production by ELISA. Cells 
were then washed twice with ice-cold PBS and submitted to protein analysis. We 
found that IRS 661 treatment can suppress CXCL8 production and BZLF1 expression 
in M81 WT LCLs (Fig. 3.27).  
From this series of results, we conclude that the impact of EBER2 on EBV lytic 
replication required a functional TLR7, a sensor of viral single-stranded RNA 
(ssRNA). 
                                                               
C
on
tro
l 
IR
S
 6
61
 
actin 
BZLF1 36 kDa  
42 kDa  
	 110	
Fig. 3.27 CXCL8 production is decreased after treatment with the TLR7 
antagonist. We assessed CXCL8 expression by ELISA on LCLs transformed by M81 
wild type after treating with TLR7 antagonist IRS 661 (10 µM) (left graph). The data 
shows the mean of three independent experiments ± SD. We performed immunoblot 
analyses on IRS 661-treated-LCLs with antibodies specific for BZLF1 and actin 
(middle picture). The middle picture shows one sample and the right graph represents 
three independent experiments. 
 
3.9.4 Proposed Model 
In summary, we found that the number of cells in which lytic replication takes place 
is increased both in vitro and in vivo by the non-coding RNA EBER2, but not by its 
homolog on the B95-8 genome. These two EBER2 RNAs display a limited number of 
polymorphisms, some of which influence their half-life and expression levels. M81 
EBER2 modified the expression of a large number of cellular genes including 
CXCL8. This chemokine was able to compensate the absence of EBER2, suggesting 
that it represents the main target of this non-coding RNA. We found that the exosomal 
fraction of B cells infected with wild type M81 that carries the EBER molecules, are 
able to increase CXCL8 and BZLF1 production and thus partly complement the 
phenotype of B cells infected with a virus that lacks the EBER RNAs. The effect of 
EBER2 on EBV lytic replication required a functional TLR7, a sensor of viral single-
stranded RNA (ssRNA). Therefore, we propose a model in which EBERs are vehicled 
into the exosomal fraction of infected B cells to initiate lytic replication in a paracrine 
manner through CXCL8 secretion induced by TLR7 stimulation (Fig. 3.28). These 
results indicate that EBERs from a NPC-derived virus variant contribute to lytic 
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replication in B cells and activate production of a chemokine involved in 
carcinogenesis. 
 
 
Fig. 3.28 Working model. We propose a model in which EBERs are vehicled into 
the exosomal fraction of infected B cells to initiate lytic replication in a paracrine 
manner through CXCL8 secretion induced by TLR7 stimulation.  
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4 Discussion 
The Epstein-Barr virus (EBV) M81 strain was isolated from a carcinoma and induces 
potent spontaneous virus production in infected B cells. M81 lytic replication was 
found to induce chromosome instability, offering a direct link between both events. 
Thus, the study of the mechanisms that mediate M81’s ability to replicate is also 
important to study its oncogenic properties. We found that the non-coding RNA 
EBER2 potentiated lytic replication both in vitro and in vivo, but that this property 
was not shared by its homolog from the B95-8 EBV strain. M81 and B95-8 EBER2 
homologs displayed a limited number of polymorphisms, some of which influence 
their half-life and expression levels.  M81 EBER2 modified the expression of a large 
number of cellular genes including CXCL8. This chemokine was able to compensate 
the absence of EBER2, suggesting that it represents the main target of this non-coding 
RNA. We found that the exosomal fraction of B cells infected with wild type M81 
carries the EBER molecules and is able to increase CXCL8 and to launch virus 
production but that this effect required a functional TLR7, a sensor of viral single-
stranded RNA (ssRNA). Therefore, we propose a model in which EBERs are vehicled 
into the exosomal fraction of infected B cells to initiate lytic replication in a paracrine 
manner through CXCL8 secretion induced by TLR7 stimulation. These results 
indicate that M81 EBERs contribute to lytic replication in B cells and activate 
production of a chemokine involved in inflammation and carcinogenesis. 
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4.1 EBV strains derived from NPC carry a unique EBER2 
sequence 
The pathogenesis of NPC remains unclear. Biopsies of NPC show expression of the 
EBERs, EBNA1, and BART miRNAs, that is accompanied by weak and patchy 
expression of LMP1 and LMP2A/B. This form of EBV latency, also known as latency 
II, was subsequently found in cases of EBV-associated Hodgkin lymphoma (HL) 
(Young and Dawson, 2014). However, the expression of these viral products remains 
unsufficient to transform epithelial cells. 
EBV lytic replication is a major risk factor for the development of EBV-positive 
nasopharyngeal carcinoma (NPC). The geographical distribution of NPC is mainly 
but not entirely restricted to South East Asia (Busson et al., 2004). What causes this 
distribution in disease incidence is unclear, although the age at which EBV infection 
takes place, environmental factors such as food contaminations with nitrosamines and 
phorbol esters or smoking, are all known to play an important role (Hsu and Glaser, 
2000; Hsu et al., 2009; Jia and Qin, 2012; Yu and Yuan, 2002). The genetic 
background of the affected individuals has also been invoked to explain this puzzling 
phenomenon (Hildesheim et al., 1997; Li et al., 2009; Lu et al., 1990; Ung et al., 
1999). Another nonexclusive hypothesis is that the occurrence of these diseases 
reflects the existence of multiple virus subtypes that are endowed with different 
properties but are found only in restricted geographic areas. Strong evidence for 
genetic polymorphisms between EBV isolates has been garnered from partial or total 
sequencing of multiple viruses from all over the world (Feederle et al., 2015).  
By performing alignments in 172 EBV genomes, we found that EBV strains from 
NPC, frequently carry EBER2 polymorphisms that differs from the EBV strains 
derived from benign and tumor lesions such as Burkitt’s lymphomas (BL) and gastric 
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carcinomas (GC). This suggests that NPC strains carry unique EBER2 sequences. 
EBER recombinants have been engineered and introduced into host B-lymphocytes. 
All these observations indicate that M81 EBER2 derived from NPC might have 
unique functions. M81 EBER2 polymorphisms influenced multiple parameters 
including half-life and expression levels. Therefore, we think that the EBER2 RNA 
might play an important role in the development of NPC through its role on lytic 
replication.  
 
4.2 Functional analysis of EBERs in lytic replication in vitro 
and in vivo  
The functions served by the EBERs in the infected cells have been controversially 
discussed since their identification. Early papers found that deletion of the EBERs 
does not influence lytic replication in a model of replication induced by TPA 
(Swaminathan et al., 1991). More recently, EBER2 has been proposed to increase 
lytic replication. Lee et al reported that knockdown of EBER2 decreases EBV lytic 
replication in replication-permissive EBV-positive cell line HH514-16 with sodium 
butyrate. Interestingly, EBER2 knockdown did not affect the expression of BZLF1 
that is important for the initiation of lytic replication (Lee et al., 2015). Thus, the 
effects described in this paper are not related to our own results. 
We used a model of spontaneous lytic replication combined to knockout viruses from 
two viral strains lacking the EBERs in primary B cells to analyze their impact on lytic 
replication. We concluded that M81 EBER2, but not B95-8 EBER2, increases the 
frequency of lytic replication initiation in infected B cells, although some degree of 
lytic replication remained visible in cells infected with the mutant virus. It is 
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important to note that the EBERs only amplify spontaneous lytic replication but do 
not initiate it, a finding in line with the observation that cells infected with 
M81/∆E1+2 still show some degree of lytic replication. The positive contribution of 
EBER2 to M81 replication could be confirmed by complementation assays. Here we 
found that transfection of the M81 EBERs, but not of the B95-8 EBERs, restored 
BZLF1 expression in B cells infected with the M81/∆E1+2 mutant.  
M81 EBER2 possesses unique polymorphisms but M81-infected cells also express 
this non-coding RNA at much higher levels than cells infected with other virus 
strains. Thus, both the quantity and the sequence of the M81 EBER2 might explain its 
ability to boost replication. However, complementation of the M81/∆E1+2 mutant 
with either M81 and B95-8 EBERs cloned under an inducible promoter led to nearly 
similar expression levels. Because the B95-8 EBER2 did not complement 
M81/∆E1+2 efficiently despite being expressed at the same levels as M81 EBER2, 
this suggests that polymorphisms between both types of EBERs rather than 
differences in expression levels explain the differences between the viral isolates. 
However, this does not mean that the high levels of EBER expression in M81 plays 
no role in the amplification of replication. Indeed, the increase in lytic replication 
induced by the M81 EBER2 is dose-dependent. We also evaluated the role played by 
EBER in the control of lytic replication using an in vivo model of EBV infection and 
injected resting B cells exposed to M81/∆E1+2 or M81/∆E1+2 Rev viruses to into 
immuno-suppressed NSG mice. We found that mice infected with the M81/∆E1+2 
mutant also showed a reduction in expression of the lytic proteins as reported in vitro. 
We conclude that the non-coding RNA EBER2 potentiated lytic replication both in 
vitro and in vivo in a mice model.  
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The larger amounts of EBER present in M81-infected cells could partly be ascribed to 
an increased half life of the M81, relative to B95-8 EBER2. Four of the M81-specific 
polymophisms explain this differential behavior and mutation of any of these sites 
clearly modifies the abundance of the non-coding RNA. However, we also found that 
the replicating cells themselves produce very large amounts of EBERs. Indeed, 
induction of lytic replication through transfection of BZLF1 massively increases the 
amount of EBER2, and to a lower extent of EBER1, produced in the cells. A previous 
paper reported that EBER-1 and EBER-2 were downregulated during the switch to 
lytic viral replication (Greifenegger et al., 1998).  In contrast, another paper reported 
that EBER1 and EBER2 were upregulated in Akata cell line following IgG cross-
linking-induced replication (Yuan et al., 2006). These discrepancies could be 
explained by the different experimental systems used in the different studies.  
It remains unclear at this point whether the BZLF1 protein directly transactivates the 
promoter elements of the EBER RNAs or indirectly incluence some viral or cellular 
proteins that play a role in the EBER expression. Although only few cells undergo 
lytic replication, the massive production of EBER by these cells is likely to influence 
the global EBER production of the infected cell population. Thus, multiple 
mechanisms converge to explain the high levels of EBER2 production in M81-
infected cells.   
We currently do not know how the M81 EBER2 polymorphisms render the molecule 
active. We know that they influence the half-life and thus the global production of 
EBER2. Furthermore, they might influence the global structure of the EBER2 RNA 
or modify the multiple RNA-protein interactions of EBER2 that were presented in the 
introduction. It is interesting to note that the EBER2 polymorphisms are located in a 
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region of the molecule that has previously been found to interact with the terminal 
repeats of the viral DNA molecule (Please see paragraph 4.4). 
 
4.3 M81 EBER2 amplifies CXCL8 through TLR7 to 
promote lytic replication 
Using a RNA microarray analysis and a Human Cytokine Array, we found that M81 
EBER2 induces the expression of CXCL8 in infected cells, a chemokine that 
stimulates the intensity of replication in infected cells. This effect was specific to the 
M81 EBER2 molecule and not shared with its B95-8 homolog and this probably 
explains why only M81 EBER2 potentiated lytic replication but not by B95-8 
EBER2. CXCL8 is a chemokine that is secreted as a result of an activation of the 
immune system, including its innate branch. We searched for mechanisms that could 
link EBER and CXCL8 production. Because lytic replication takes place in infected B 
cells in the absence of T cells or other members of the adaptive immune response, we 
deemed it more likely that CXCL8 was activated in M81-infected B cells by the 
innate immune response. However, EBER is mainly located in the nucleus of infected 
cells and cannot a priori access restriction factors that are mainly located in the 
cytoplasm or in the endosome compartments. EBER has been reported to be 
incorporated in exosomes produced by infected cells (Ahmed et al., 2014). These 
subcellular organelles could access dendritic cells and activate TLR3 in the endosome 
(Iwakiri et al., 2009). 
We tested whether such a mechanism could also act in a paracrine manner. However, 
TLR3 is not expressed in B cells. We canvassed a transcriptome of EBV-infected B 
cells and looked at the expression of TLR members expressed in the endosome. This 
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analysis confirmed that while TLR3 and TLR8 are hardly expressed in infected B 
cells, TLR7 is expressed in these cells, as previously reported (Hanten et al., 2008).  
We found that the effect of EBER2 on lytic replication via CXCL8 stimulation could 
be reproduced by exposing infected cells to exosomes from LCLs infected with wild 
type M81 virus, a subcellular structure that was previously identified by several 
authors to contain EBERs in association with the La protein (Iwakiri et al., 2009). 
Extracellular EBERs were previously found to activate TLR3 in NK cells and in T 
cells, leading to the release of IFN beta and gamma, together with TNF alpha (Iwakiri 
et al., 2009). We could not identify such an effect in M81-infected B cells that neither 
express TLR3, nor secrete these latter cytokines. A major difference between the 
present and the published experimental systems is that the latter used transfected 
EBER molecules that are likely to reach cytoplasmic structures where they could 
induce signaling, e.g. after recognition by RIG-I, although EBERs are typically 
nuclear in location. Instead we found a link between EBER, CXCL8 expression and 
TLR7 activation. TLR7 is located in the cellular endosome and its expression is up 
regulated by the EBV infection (Martin et al., 2007). The results of the cytokine array 
and of the transcriptome analysis make us confident that the positive impact of 
EBERs on cytokines in LCLs infected by M81 is limited to CXCL8 and that TLR7 is 
implicated in that process. We could show that the EBER complex contained in the 
exosomes is sufficient to include CXCL8 expression and lytic replication, although it 
remains possible that EBER2 also accesses infected cells through another route. 
Similarly, M81 EBER2 might also interact with cellular PAMPs other than TLR7. It 
is interesting to note that lytic replication itself strongly enhances EBER production 
within replicating cells. This increased production might enhance the total 
concentration of EBER in exosomes of the extracellular milieu and contribute to the 
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induction of lytic replication in neighboring cells, thereby building a self-reinforcing 
positive loop.  
Interestingly, we found that the effect of EBER2 on lytic replication via CXCL8 
stimulation could not be reproduced by exposing infected cells to exosomes from 
LCLs infected with wild type B95-8 virus.  
Researchers reported that guanosine (G)- and uridine (U)-rich ssRNA 
oligonucleotides derived from human immunodeficiency virus-1 (HIV-1) stimulate 
dendritic cells (DC) and macrophages to secrete interferon-α  and proinflammatory, as 
well as regulatory cytokines. These data suggest that ssRNA represents a 
physiological ligand for TLR7 and TLR8 (Heil et al., 2004). Forsbach et al then 
identified GU-rich Oligoribonucleotides (ORNs) as TLR7/8 RNA ligands that 
stimulate human TLR7 and TLR8 immune responses (Forsbach et al., 2008).  
We reported that M81 carries EBER2 polymorphisms that generate a GU-rich 
sequence. Whether these EBER2 polymorphisms influence the TLR7 recognization is 
currently under investigation.  
We conclude from this set of data that the non-coding RNA M81 EBER2 induced 
inflammation in a paracrine manner to enhance virus production. However, it is 
important to note that cells undergoing lytic replication remain a minority, although 
all cells are in contact with exosomes, demonstrating that additional mechanisms that 
negatively control lytic replication exist. We found one of these mechanisms, as only 
40% of cells incorporate EBERs, presumably because they actively block endocytosis 
of EBER-containing exosomes. These observations have important consequences for 
the pathogenesis of EBV-associated tumors. Elevated chronic CXCL8 production is a 
well-established cancer risk. Furthermore, carcinoma cells from nasopharyngeal 
carcinoma cells that are infected with the Epstein-Barr virus frequently express high 
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levels of CXCL8. This identifies a second M81-specific oncogenic trait after the 
ability of the M81 particles to induce centrosome overduplication. 
 
4.4 Interplay between LMP1/2 and the EBER RNAs 
EBER2 has previously been implicated in the lytic replication induced by sodium 
butyrate in the Burkitt’s lymphoma cell line HH514, although the precise role of 
EBER2 in this process is not clear from this study. The authors found that EBER2 
facilitates recruitment of PAX5 to the LMP1 and LMP2 transcripts through RNA-
RNA association between EBER2 and the terminal repeats sequences found in the 
5’UTR of the viral latent proteins. This interaction was suggested to facilitate DNA 
replication, although the precise mechanism that underlies this function remains 
unknown (Lee et al., 2015). There are many differences between this study and the 
currently presented. First, we could not gather any evidence that EBER2 influences 
transcription of M81 LMP1 and LMP2.  These transcripts varied in amplitude over a 
period of 3 months and were actually expressed slightly more in cells infected with 
the ∆EBER knockout. However, it is interesting to note that we observed such an 
effect in cells infected with B95-8, suggesting another difference between B95-8 and 
M81. It is noteworthy that the four polymorphisms that characterize M81 EBER2 are 
located in the EBER region that were found to interact with the terminal repeats, 
thereby possibly explaining the absence of modification of LMP1 and 2 transcription 
in cells infected with M81/∆EBER1+2. Although LMP1 and LMP2 transcription is 
mildly up regulated in cells infected with B95-8/∆EBER, this deletion had no effect 
on the rate of lytic replication in infected cells as cells remained non-permissive to 
lytic replication. Thus, the effects of EBER2 on lytic replication described in the 
study by Lee et al. are distinct from those reported in the present study. The cellular 
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background might also play a role in the effect served by EBER2.  Earlier studies 
found that the deletion of EBER2 had no influence on the lytic replication of primary 
B cells transformed with an EBER-null virus constructed on the basis of P3HR1 and 
induced with TPA (Swaminathan et al., 1991). Therefore, the EBER deletion has a 
different effect in transformed B cells and in Burkitt’s lymphoma B cells. 
 
4.5 The relationship between CXCL8 and NPC 
Nasopharyngeal carcinoma (NPC) has a high incidence rate in southern China and 
southeast Asia. Among head and neck cancers, NPC has the highest metastasis rate 
(Ahmad and Stefani, 1986; Lee et al., 1993): at the time of diagnosis: 74.5% of 
patients present with regional lymph node metastasis and 19.9% present with distant 
metastasis (Huang et al., 1996; Wei and Mok, 2007). Distant metastasis is therefore 
the major cause of treatment failure, although NPC is sensitive to radio-therapy.  
Epstein-Barr virus infection has been closely linked to NPC (Dong et al., 2012; Ji et 
al., 2011; Liang et al., 2012). It has been observed that CXCL8 expression in NPC 
cells can also be induced by Epstein–Barr virus proteins (Hsu et al., 2008; Ren et al., 
2004; Yoshizaki et al., 2001). Here, we have identified that CXCL8 expression in B 
cells can be enhanced by EBV-encoded RNAs.  
Previous papers report that CXCL8 serves as an independent prognostic indicator of 
overall survival, disease-free survival, and metastasis-free survival for patients with 
NPC. CXCL8 promotes NPC metastasis via autocrine and paracrine means, involving 
activation of AKT signaling and inducing EMT in NPC cells (Liu et al., 2012). 
Our study suggests that drugs against CXCL8 receptor could be firstly tested in mice 
model and in case of success could possibly be tested in clinical trials.  
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